
Title:
Estrogen
Text:
Primary female sex hormone
.mw-parser-output .hatnote{font-style:italic}.mw-parser-output div.hatnote{padding-left:1.6em;margin-bottom:0.5em}.mw-parser-output .hatnote i{font-style:normal}.mw-parser-output .hatnote+link+.hatnote{margin-top:-0.5em}This article is about estrogens as hormones. For their use as medications, see Estrogen (medication).


.mw-parser-output .infobox-subbox{padding:0;border:none;margin:-3px;width:auto;min-width:100%;font-size:100%;clear:none;float:none;background-color:transparent}.mw-parser-output .infobox-3cols-child{margin:auto}.mw-parser-output .infobox .navbar{font-size:100%}body.skin-minerva .mw-parser-output .infobox-header,body.skin-minerva .mw-parser-output .infobox-subheader,body.skin-minerva .mw-parser-output .infobox-above,body.skin-minerva .mw-parser-output .infobox-title,body.skin-minerva .mw-parser-output .infobox-image,body.skin-minerva .mw-parser-output .infobox-full-data,body.skin-minerva .mw-parser-output .infobox-below{text-align:center}EstrogenDrug classEstradiol, the major estrogen sex hormone in humans and a widely used medication.Class identifiersUseContraception, menopause, hypogonadism, transgender women, prostate cancer, breast cancer, othersATC codeG03CBiological targetEstrogen receptors (ERα, ERβ, mERs (e.g., GPER, others))External linksMeSHD004967In Wikidata
Estrogen or oestrogen is a category of sex hormone responsible for the development and regulation of the female reproductive system and secondary sex characteristics.[1][2] There are three major endogenous estrogens that have estrogenic hormonal activity: estrone (E1), estradiol (E2), and estriol (E3).[1][3] Estradiol, an estrane, is the most potent and prevalent.[1] Another estrogen called estetrol (E4) is produced only during pregnancy.
Estrogens are synthesized in all vertebrates[4] and some insects.[5] Their presence in both vertebrates and insects suggests that estrogenic sex hormones have an ancient evolutionary history. Quantitatively, estrogens circulate at lower levels than androgens in both men and women.[6] While estrogen levels are significantly lower in males than in females, estrogens nevertheless have important physiological roles in males.[7]
Like all steroid hormones, estrogens readily diffuse across the cell membrane. Once inside the cell, they bind to and activate estrogen receptors (ERs) which in turn modulate the expression of many genes.[8] Additionally, estrogens bind to and activate rapid-signaling membrane estrogen receptors (mERs),[9][10] such as GPER (GPR30).[11]
In addition to their role as natural hormones, estrogens are used as medications, for instance in menopausal hormone therapy, hormonal birth control and feminizing hormone therapy for transgender women and nonbinary people.

.mw-parser-output .toclimit-2 .toclevel-1 ul,.mw-parser-output .toclimit-3 .toclevel-2 ul,.mw-parser-output .toclimit-4 .toclevel-3 ul,.mw-parser-output .toclimit-5 .toclevel-4 ul,.mw-parser-output .toclimit-6 .toclevel-5 ul,.mw-parser-output .toclimit-7 .toclevel-6 ul{display:none}Contents

1 Types and examples
2 Biological function

2.1 Overview of actions
2.2 Female pubertal development

2.2.1 Breast development


2.3 Female reproductive system
2.4 Neuroprotection and DNA repair
2.5 Brain and behavior

2.5.1 Sex drive
2.5.2 Cognition
2.5.3 Mental health
2.5.4 Parenthood
2.5.5 Binge eating
2.5.6 Masculinization in rodents


2.6 Skeletal system
2.7 Cardiovascular system
2.8 Immune system
2.9 Associated conditions


3 Biochemistry

3.1 Biosynthesis
3.2 Distribution
3.3 Metabolism
3.4 Excretion


4 Medical use
5 Chemistry
6 History
7 Society and culture

7.1 Etymology
7.2 Environment
7.3 Cosmetics


8 See also
9 References
10 External links



Types and examples[edit]





.mw-parser-output .navbar{display:inline;font-size:88%;font-weight:normal}.mw-parser-output .navbar-collapse{float:left;text-align:left}.mw-parser-output .navbar-boxtext{word-spacing:0}.mw-parser-output .navbar ul{display:inline-block;white-space:nowrap;line-height:inherit}.mw-parser-output .navbar-brackets::before{margin-right:-0.125em;content:"[ "}.mw-parser-output .navbar-brackets::after{margin-left:-0.125em;content:" ]"}.mw-parser-output .navbar li{word-spacing:-0.125em}.mw-parser-output .navbar a>span,.mw-parser-output .navbar a>abbr{text-decoration:inherit}.mw-parser-output .navbar-mini abbr{font-variant:small-caps;border-bottom:none;text-decoration:none;cursor:inherit}.mw-parser-output .navbar-ct-full{font-size:114%;margin:0 7em}.mw-parser-output .navbar-ct-mini{font-size:114%;margin:0 4em}vte Structures of major endogenous estrogens

 
 

Estrone (E1)
Estradiol (E2)
Estriol (E3)
Estetrol (E4)


Note the hydroxyl (–OH) groups: estrone (E1) has one, estradiol (E2) has two, estriol (E3) has three, and estetrol (E4) has four.



The four major naturally occurring estrogens in women are estrone (E1), estradiol (E2), estriol (E3), and estetrol (E4). Estradiol is the predominant estrogen during reproductive years both in terms of absolute serum levels as well as in terms of estrogenic activity. During menopause, estrone is the predominant circulating estrogen and during pregnancy estriol is the predominant circulating estrogen in terms of serum levels. Given by subcutaneous injection in mice, estradiol is about 10-fold more potent than estrone and about 100-fold more potent than estriol.[12] Thus, estradiol is the most important estrogen in non-pregnant females who are between the menarche and menopause stages of life. However, during pregnancy this role shifts to estriol, and in postmenopausal women estrone becomes the primary form of estrogen in the body. Another type of estrogen called estetrol (E4) is produced only during pregnancy. All of the different forms of estrogen are synthesized from androgens, specifically testosterone and androstenedione, by the enzyme aromatase.
Minor endogenous estrogens, the biosyntheses of which do not involve aromatase, include 27-hydroxycholesterol, dehydroepiandrosterone (DHEA), 7-oxo-DHEA, 7α-hydroxy-DHEA, 16α-hydroxy-DHEA, 7β-hydroxyepiandrosterone, androstenedione (A4), androstenediol (A5), 3α-androstanediol, and 3β-androstanediol.[13][14] Some estrogen metabolites, such as the catechol estrogens 2-hydroxyestradiol, 2-hydroxyestrone, 4-hydroxyestradiol, and 4-hydroxyestrone, as well as 16α-hydroxyestrone, are also estrogens with varying degrees of activity.[15] The biological importance of these minor estrogens is not entirely clear.

Biological function[edit]
  Reference ranges for the blood content of estradiol, the primary type of estrogen, during the menstrual cycle.[16]
The actions of estrogen are mediated by the estrogen receptor (ER), a dimeric nuclear protein that binds to DNA and controls gene expression. Like other steroid hormones, estrogen enters passively into the cell where it binds to and activates the estrogen receptor. The estrogen:ER complex binds to specific DNA sequences called a hormone response element to activate the transcription of target genes (in a study using an estrogen-dependent breast cancer cell line as model, 89 such genes were identified).[17] Since estrogen enters all cells, its actions are dependent on the presence of the ER in the cell. The ER is expressed in specific tissues including the ovary, uterus and breast. The metabolic effects of estrogen in postmenopausal women have been linked to the genetic polymorphism of the ER.[18]
While estrogens are present in both men and women, they are usually present at significantly higher levels in women of reproductive age. They promote the development of female secondary sexual characteristics, such as breasts, and are also involved in the thickening of the endometrium and other aspects of regulating the menstrual cycle. In males, estrogen regulates certain functions of the reproductive system important to the maturation of sperm[19][20][21] and may be necessary for a healthy libido.[22]


vte Affinities of estrogen receptor ligands for the ERα and ERβ


Ligand
Other names
Relative binding affinities (RBA, %)a
Absolute binding affinities (Ki, nM)a
Action


ERα
ERβ
ERα
ERβ


Estradiol
E2; 17β-Estradiol
100
100
0.115  (0.04–0.24)
0.15  (0.10–2.08)
Estrogen


Estrone
E1; 17-Ketoestradiol
16.39  (0.7–60)
6.5  (1.36–52)
0.445  (0.3–1.01)
1.75  (0.35–9.24)
Estrogen


Estriol
E3; 16α-OH-17β-E2
12.65  (4.03–56)
26  (14.0–44.6)
0.45  (0.35–1.4)
0.7  (0.63–0.7)
Estrogen


Estetrol
E4; 15α,16α-Di-OH-17β-E2
4.0
3.0
4.9
19
Estrogen


Alfatradiol
17α-Estradiol
20.5  (7–80.1)
8.195  (2–42)
0.2–0.52
0.43–1.2
Metabolite


16-Epiestriol
16β-Hydroxy-17β-estradiol
7.795  (4.94–63)
50
?
?
Metabolite


17-Epiestriol
16α-Hydroxy-17α-estradiol
55.45  (29–103)
79–80
?
?
Metabolite


16,17-Epiestriol
16β-Hydroxy-17α-estradiol
1.0
13
?
?
Metabolite


2-Hydroxyestradiol
2-OH-E2
22  (7–81)
11–35
2.5
1.3
Metabolite


2-Methoxyestradiol
2-MeO-E2
0.0027–2.0
1.0
?
?
Metabolite


4-Hydroxyestradiol
4-OH-E2
13  (8–70)
7–56
1.0
1.9
Metabolite


4-Methoxyestradiol
4-MeO-E2
2.0
1.0
?
?
Metabolite


2-Hydroxyestrone
2-OH-E1
2.0–4.0
0.2–0.4
?
?
Metabolite


2-Methoxyestrone
2-MeO-E1
<0.001–<1
<1
?
?
Metabolite


4-Hydroxyestrone
4-OH-E1
1.0–2.0
1.0
?
?
Metabolite


4-Methoxyestrone
4-MeO-E1
<1
<1
?
?
Metabolite


16α-Hydroxyestrone
16α-OH-E1; 17-Ketoestriol
2.0–6.5
35
?
?
Metabolite


2-Hydroxyestriol
2-OH-E3
2.0
1.0
?
?
Metabolite


4-Methoxyestriol
4-MeO-E3
1.0
1.0
?
?
Metabolite


Estradiol sulfate
E2S; Estradiol 3-sulfate
<1
<1
?
?
Metabolite


Estradiol disulfate
Estradiol 3,17β-disulfate
0.0004
?
?
?
Metabolite


Estradiol 3-glucuronide
E2-3G
0.0079
?
?
?
Metabolite


Estradiol 17β-glucuronide
E2-17G
0.0015
?
?
?
Metabolite


Estradiol 3-gluc. 17β-sulfate
E2-3G-17S
0.0001
?
?
?
Metabolite


Estrone sulfate
E1S; Estrone 3-sulfate
<1
<1
>10
>10
Metabolite


Estradiol benzoate
EB; Estradiol 3-benzoate
10
?
?
?
Estrogen


Estradiol 17β-benzoate
E2-17B
11.3
32.6
?
?
Estrogen


Estrone methyl ether
Estrone 3-methyl ether
0.145
?
?
?
Estrogen


ent-Estradiol
1-Estradiol
1.31–12.34
9.44–80.07
?
?
Estrogen


Equilin
7-Dehydroestrone
13  (4.0–28.9)
13.0–49
0.79
0.36
Estrogen


Equilenin
6,8-Didehydroestrone
2.0–15
7.0–20
0.64
0.62
Estrogen


17β-Dihydroequilin
7-Dehydro-17β-estradiol
7.9–113
7.9–108
0.09
0.17
Estrogen


17α-Dihydroequilin
7-Dehydro-17α-estradiol
18.6  (18–41)
14–32
0.24
0.57
Estrogen


17β-Dihydroequilenin
6,8-Didehydro-17β-estradiol
35–68
90–100
0.15
0.20
Estrogen


17α-Dihydroequilenin
6,8-Didehydro-17α-estradiol
20
49
0.50
0.37
Estrogen


Δ8-Estradiol
8,9-Dehydro-17β-estradiol
68
72
0.15
0.25
Estrogen


Δ8-Estrone
8,9-Dehydroestrone
19
32
0.52
0.57
Estrogen


Ethinylestradiol
EE; 17α-Ethynyl-17β-E2
120.9  (68.8–480)
44.4  (2.0–144)
0.02–0.05
0.29–0.81
Estrogen


Mestranol
EE 3-methyl ether
?
2.5
?
?
Estrogen


Moxestrol
RU-2858; 11β-Methoxy-EE
35–43
5–20
0.5
2.6
Estrogen


Methylestradiol
17α-Methyl-17β-estradiol
70
44
?
?
Estrogen


Diethylstilbestrol
DES; Stilbestrol
129.5  (89.1–468)
219.63  (61.2–295)
0.04
0.05
Estrogen


Hexestrol
Dihydrodiethylstilbestrol
153.6  (31–302)
60–234
0.06
0.06
Estrogen


Dienestrol
Dehydrostilbestrol
37  (20.4–223)
56–404
0.05
0.03
Estrogen


Benzestrol (B2)
–
114
?
?
?
Estrogen


Chlorotrianisene
TACE
1.74
?
15.30
?
Estrogen


Triphenylethylene
TPE
0.074
?
?
?
Estrogen


Triphenylbromoethylene
TPBE
2.69
?
?
?
Estrogen


Tamoxifen
ICI-46,474
3  (0.1–47)
3.33  (0.28–6)
3.4–9.69
2.5
SERM


Afimoxifene
4-Hydroxytamoxifen; 4-OHT
100.1  (1.7–257)
10  (0.98–339)
2.3  (0.1–3.61)
0.04–4.8
SERM


Toremifene
4-Chlorotamoxifen; 4-CT
?
?
7.14–20.3
15.4
SERM


Clomifene
MRL-41
25  (19.2–37.2)
12
0.9
1.2
SERM


Cyclofenil
F-6066; Sexovid
151–152
243
?
?
SERM


Nafoxidine
U-11,000A
30.9–44
16
0.3
0.8
SERM


Raloxifene
–
41.2  (7.8–69)
5.34  (0.54–16)
0.188–0.52
20.2
SERM


Arzoxifene
LY-353,381
?
?
0.179
?
SERM


Lasofoxifene
CP-336,156
10.2–166
19.0
0.229
?
SERM


Ormeloxifene
Centchroman
?
?
0.313
?
SERM


Levormeloxifene
6720-CDRI; NNC-460,020
1.55
1.88
?
?
SERM


Ospemifene
Deaminohydroxytoremifene
0.82–2.63
0.59–1.22
?
?
SERM


Bazedoxifene
–
?
?
0.053
?
SERM


Etacstil
GW-5638
4.30
11.5
?
?
SERM


ICI-164,384
–
63.5  (3.70–97.7)
166
0.2
0.08
Antiestrogen


Fulvestrant
ICI-182,780
43.5  (9.4–325)
21.65  (2.05–40.5)
0.42
1.3
Antiestrogen


Propylpyrazoletriol
PPT
49  (10.0–89.1)
0.12
0.40
92.8
ERα agonist


16α-LE2
16α-Lactone-17β-estradiol
14.6–57
0.089
0.27
131
ERα agonist


16α-Iodo-E2
16α-Iodo-17β-estradiol
30.2
2.30
?
?
ERα agonist


Methylpiperidinopyrazole
MPP
11
0.05
?
?
ERα antagonist


Diarylpropionitrile
DPN
0.12–0.25
6.6–18
32.4
1.7
ERβ agonist


8β-VE2
8β-Vinyl-17β-estradiol
0.35
22.0–83
12.9
0.50
ERβ agonist


Prinaberel
ERB-041; WAY-202,041
0.27
67–72
?
?
ERβ agonist


ERB-196
WAY-202,196
?
180
?
?
ERβ agonist


Erteberel
SERBA-1; LY-500,307
?
?
2.68
0.19
ERβ agonist


SERBA-2
–
?
?
14.5
1.54
ERβ agonist


Coumestrol
–
9.225  (0.0117–94)
64.125  (0.41–185)
0.14–80.0
0.07–27.0
Xenoestrogen


Genistein
–
0.445  (0.0012–16)
33.42  (0.86–87)
2.6–126
0.3–12.8
Xenoestrogen


Equol
–
0.2–0.287
0.85  (0.10–2.85)
?
?
Xenoestrogen


Daidzein
–
0.07  (0.0018–9.3)
0.7865  (0.04–17.1)
2.0
85.3
Xenoestrogen


Biochanin A
–
0.04  (0.022–0.15)
0.6225  (0.010–1.2)
174
8.9
Xenoestrogen


Kaempferol
–
0.07  (0.029–0.10)
2.2  (0.002–3.00)
?
?
Xenoestrogen


Naringenin
–
0.0054  (<0.001–0.01)
0.15  (0.11–0.33)
?
?
Xenoestrogen


8-Prenylnaringenin
8-PN
4.4
?
?
?
Xenoestrogen


Quercetin
–
<0.001–0.01
0.002–0.040
?
?
Xenoestrogen


Ipriflavone
–
<0.01
<0.01
?
?
Xenoestrogen


Miroestrol
–
0.39
?
?
?
Xenoestrogen


Deoxymiroestrol
–
2.0
?
?
?
Xenoestrogen


β-Sitosterol
–
<0.001–0.0875
<0.001–0.016
?
?
Xenoestrogen


Resveratrol
–
<0.001–0.0032
?
?
?
Xenoestrogen


α-Zearalenol
–
48  (13–52.5)
?
?
?
Xenoestrogen


β-Zearalenol
–
0.6  (0.032–13)
?
?
?
Xenoestrogen


Zeranol
α-Zearalanol
48–111
?
?
?
Xenoestrogen


Taleranol
β-Zearalanol
16  (13–17.8)
14
0.8
0.9
Xenoestrogen


Zearalenone
ZEN
7.68  (2.04–28)
9.45  (2.43–31.5)
?
?
Xenoestrogen


Zearalanone
ZAN
0.51
?
?
?
Xenoestrogen


Bisphenol A
BPA
0.0315  (0.008–1.0)
0.135  (0.002–4.23)
195
35
Xenoestrogen


Endosulfan
EDS
<0.001–<0.01
<0.01
?
?
Xenoestrogen


Kepone
Chlordecone
0.0069–0.2
?
?
?
Xenoestrogen


o,p'-DDT
–
0.0073–0.4
?
?
?
Xenoestrogen


p,p'-DDT
–
0.03
?
?
?
Xenoestrogen


Methoxychlor
p,p'-Dimethoxy-DDT
0.01  (<0.001–0.02)
0.01–0.13
?
?
Xenoestrogen


HPTE
Hydroxychlor; p,p'-OH-DDT
1.2–1.7
?
?
?
Xenoestrogen


Testosterone
T; 4-Androstenolone
<0.0001–<0.01
<0.002–0.040
>5000
>5000
Androgen


Dihydrotestosterone
DHT; 5α-Androstanolone
0.01  (<0.001–0.05)
0.0059–0.17
221–>5000
73–1688
Androgen


Nandrolone
19-Nortestosterone; 19-NT
0.01
0.23
765
53
Androgen


Dehydroepiandrosterone
DHEA; Prasterone
0.038  (<0.001–0.04)
0.019–0.07
245–1053
163–515
Androgen


5-Androstenediol
A5; Androstenediol
6
17
3.6
0.9
Androgen


4-Androstenediol
–
0.5
0.6
23
19
Androgen


4-Androstenedione
A4; Androstenedione
<0.01
<0.01
>10000
>10000
Androgen


3α-Androstanediol
3α-Adiol
0.07
0.3
260
48
Androgen


3β-Androstanediol
3β-Adiol
3
7
6
2
Androgen


Androstanedione
5α-Androstanedione
<0.01
<0.01
>10000
>10000
Androgen


Etiocholanedione
5β-Androstanedione
<0.01
<0.01
>10000
>10000
Androgen


Methyltestosterone
17α-Methyltestosterone
<0.0001
?
?
?
Androgen


Ethinyl-3α-androstanediol
17α-Ethynyl-3α-adiol
4.0
<0.07
?
?
Estrogen


Ethinyl-3β-androstanediol
17α-Ethynyl-3β-adiol
50
5.6
?
?
Estrogen


Progesterone
P4; 4-Pregnenedione
<0.001–0.6
<0.001–0.010
?
?
Progestogen


Norethisterone
NET; 17α-Ethynyl-19-NT
0.085  (0.0015–<0.1)
0.1  (0.01–0.3)
152
1084
Progestogen


Norethynodrel
5(10)-Norethisterone
0.5  (0.3–0.7)
<0.1–0.22
14
53
Progestogen


Tibolone
7α-Methylnorethynodrel
0.5  (0.45–2.0)
0.2–0.076
?
?
Progestogen


Δ4-Tibolone
7α-Methylnorethisterone
0.069–<0.1
0.027–<0.1
?
?
Progestogen


3α-Hydroxytibolone
–
2.5  (1.06–5.0)
0.6–0.8
?
?
Progestogen


3β-Hydroxytibolone
–
1.6  (0.75–1.9)
0.070–0.1
?
?
Progestogen


Footnotes: a = (1) Binding affinity values are of the format "median (range)" (# (#–#)), "range" (#–#), or "value" (#) depending on the values available. The full sets of values within the ranges can be found in the Wiki code. (2) Binding affinities were determined via displacement studies in a variety of in-vitro systems with labeled estradiol and human ERα and ERβ proteins (except the ERβ values from Kuiper et al. (1997), which are rat ERβ). Sources: See template page.


vte Relative affinities of estrogens for steroid hormone receptors and blood proteins


Estrogen
Relative binding affinities (%)


ER
AR
PR
GR
MR
SHBG
CBG


Estradiol
100
7.9
2.6
0.6
0.13
8.7–12
<0.1


Estradiol benzoate
?
?
?
?
?
<0.1–0.16
<0.1


Estradiol valerate
2
?
?
?
?
?
?


Estrone
11–35
<1
<1
<1
<1
2.7
<0.1


Estrone sulfate
2
2
?
?
?
?
?


Estriol
10–15
<1
<1
<1
<1
<0.1
<0.1


Equilin
40
?
?
?
?
?
0


Alfatradiol
15
<1
<1
<1
<1
?
?


Epiestriol
20
<1
<1
<1
<1
?
?


Ethinylestradiol
100–112
1–3
15–25
1–3
<1
0.18
<0.1


Mestranol
1
?
?
?
?
<0.1
<0.1


Methylestradiol
67
1–3
3–25
1–3
<1
?
?


Moxestrol
12
<0.1
0.8
3.2
<0.1
<0.2
<0.1


Diethylstilbestrol
?
?
?
?
?
<0.1
<0.1


Notes: Reference ligands (100%) were progesterone for the PR, testosterone for the AR, estradiol for the ER, dexamethasone for the GR, aldosterone for the MR, dihydrotestosterone for SHBG, and cortisol for CBG. Sources: See template.


vte Affinities and estrogenic potencies of estrogen esters and ethers at the estrogen receptors


Estrogen

Other names

RBA (%)a

REP (%)b


ER

ERα

ERβ


Estradiol

E2

100

100

100


Estradiol 3-sulfate

E2S; E2-3S

?

0.02

0.04


Estradiol 3-glucuronide

E2-3G

?

0.02

0.09


Estradiol 17β-glucuronide

E2-17G

?

0.002

0.0002


Estradiol benzoate

EB; Estradiol 3-benzoate

10

1.1

0.52


Estradiol 17β-acetate

E2-17A

31–45

24

?


Estradiol diacetate

EDA; Estradiol 3,17β-diacetate

?

0.79

?


Estradiol propionate

EP; Estradiol 17β-propionate

19–26

2.6

?


Estradiol valerate

EV; Estradiol 17β-valerate

2–11

0.04–21

?


Estradiol cypionate

EC; Estradiol 17β-cypionate

?c

4.0

?


Estradiol palmitate

Estradiol 17β-palmitate

0

?

?


Estradiol stearate

Estradiol 17β-stearate

0

?

?


Estrone

E1; 17-Ketoestradiol

11

5.3–38

14


Estrone sulfate

E1S; Estrone 3-sulfate

2

0.004

0.002


Estrone glucuronide

E1G; Estrone 3-glucuronide

?

<0.001

0.0006


Ethinylestradiol

EE; 17α-Ethynylestradiol

100

17–150

129


Mestranol

EE 3-methyl ether

1

1.3–8.2

0.16


Quinestrol

EE 3-cyclopentyl ether

?

0.37

?


Footnotes: a = Relative binding affinities (RBAs) were determined via in-vitro displacement of labeled estradiol from estrogen receptors (ERs) generally of rodent uterine cytosol. Estrogen esters are variably hydrolyzed into estrogens in these systems (shorter ester chain length -> greater rate of hydrolysis) and the ER RBAs of the esters decrease strongly when hydrolysis is prevented. b = Relative estrogenic potencies (REPs) were calculated from half-maximal effective concentrations (EC50) that were determined via in-vitro β‐galactosidase (β-gal) and green fluorescent protein (GFP) production assays in yeast expressing human ERα and human ERβ. Both mammalian cells and yeast have the capacity to hydrolyze estrogen esters. c = The affinities of estradiol cypionate for the ERs are similar to those of estradiol valerate and estradiol benzoate (figure). Sources: See template page.


vte Selected biological properties of endogenous estrogens in rats


Estrogen
ER RBA (%)
Uterine weight (%)
Uterotrophy
LH levels (%)
SHBG RBA (%)


Control
–
100
–
100
–


Estradiol
100
506 ± 20
+++
12–19
100


Estrone
11 ± 8
490 ± 22
+++
?
20


Estriol
10 ± 4
468 ± 30
+++
8–18
3


Estetrol
0.5 ± 0.2
?
Inactive
?
1


17α-Estradiol
4.2 ± 0.8
?
?
?
?


2-Hydroxyestradiol
24 ± 7
285 ± 8
+b
31–61
28


2-Methoxyestradiol
0.05 ± 0.04
101
Inactive
?
130


4-Hydroxyestradiol
45 ± 12
?
?
?
?


4-Methoxyestradiol
1.3 ± 0.2
260
++
?
9


4-Fluoroestradiola
180 ± 43
?
+++
?
?


2-Hydroxyestrone
1.9 ± 0.8
130 ± 9
Inactive
110–142
8


2-Methoxyestrone
0.01 ± 0.00
103 ± 7
Inactive
95–100
120


4-Hydroxyestrone
11 ± 4
351
++
21–50
35


4-Methoxyestrone
0.13 ± 0.04
338
++
65–92
12


16α-Hydroxyestrone
2.8 ± 1.0
552 ± 42
+++
7–24
<0.5


2-Hydroxyestriol
0.9 ± 0.3
302
+b
?
?


2-Methoxyestriol
0.01 ± 0.00
?
Inactive
?
4


Notes: Values are mean ± SD or range. ER RBA = Relative binding affinity to estrogen receptors of rat uterine cytosol. Uterine weight = Percentage change in uterine wet weight of ovariectomized rats after 72 hours with continuous administration of 1 μg/hour via subcutaneously implanted osmotic pumps. LH levels = Luteinizing hormone levels relative to baseline of ovariectomized rats after 24 to 72 hours of continuous administration via subcutaneous implant. Footnotes: a = Synthetic (i.e., not endogenous). b = Atypical uterotrophic effect which plateaus within 48 hours (estradiol's uterotrophy continues linearly up to 72 hours). Sources: See template.

Overview of actions[edit]
This section is in list format but may read better as prose. You can help by converting this section, if appropriate. Editing help is available.  (October 2019)
Structural
Anabolic: Increases muscle mass and strength, speed of muscle regeneration, and bone density, increased sensitivity to exercise, protection against muscle damage, stronger collagen synthesis, increases the collagen content of connective tissues, tendons, and ligaments, but also decreases stiffness of tendons and ligaments (especially during menstruation). Decreased stiffness of tendons gives women much lower predisposition to muscle strains but soft ligaments are much more prone to injuries (ACL tears are 2-8x more common among women than men).[23][24][25][26]
Anti-inflammatory properties
Mediate formation of female secondary sex characteristics
Accelerate metabolism
Increased fat storage in some body parts such as breasts, buttocks, and legs but decreased abdominal and visceral fat (androgenic obesity).[27][28][29]Estradiol also regulates energy expenditure, body weight homeostasis, and seems to have much stronger anti-obesity effects than testosterone in general.[30]
Women tend to have lower base strength but on average have about the same increases of muscle mass in responses to resistance training as men and far faster relative increases in strength.[31][32]
Stimulate endometrial growth
Increase uterine growth
Increase vaginal lubrication
Thicken the vaginal wall
Maintenance of vessel and skin
Reduce bone resorption, increase bone formation
Protein synthesis
Increase hepatic production of binding proteins
Coagulation
Increase circulating level of factors 2, 7, 9, 10, plasminogen
Decrease antithrombin III
Increase platelet adhesiveness
Increase vWF (estrogen -> Angiotensin II -> Vasopressin)
Increase PAI-1 and PAI-2 also through Angiotensin II
Lipid
Increase HDL, triglyceride
Decrease LDL, fat deposition
Fluid balance
Salt (sodium) and water retention
Increase cortisol, SHBG
Gastrointestinal tract
Reduce bowel motility
Increase cholesterol in bile
Melanin
Increase pheomelanin, reduce eumelanin
Cancer
Support hormone-sensitive breast cancers (see section below)
Lung function
Promotes lung function by supporting alveoli (in rodents but probably in humans).[33]
Uterus lining
Estrogen together with progesterone promotes and maintains the uterus lining in preparation for implantation of fertilized egg and maintenance of uterus function during gestation period, also upregulates oxytocin receptor in myometrium
Ovulation
Surge in estrogen level induces the release of luteinizing hormone, which then triggers ovulation by releasing the egg from the Graafian follicle in the ovary.
Sexual behavior
Estrogen is required for female mammals to engage in lordosis behavior during estrus (when animals are "in heat").[34][35] This behavior is required for sexual receptivity in these mammals and is regulated by the ventromedial nucleus of the hypothalamus.[36]
Sex drive is dependent on androgen levels[37] only in the presence of estrogen, but without estrogen, free testosterone level actually decreases sexual desire (instead of increases sex drive), as demonstrated for those women who have hypoactive sexual desire disorder, and the sexual desire in these women can be restored by administration of estrogen (using oral contraceptive).[38]
Female pubertal development[edit]
Estrogens are responsible for the development of female secondary sexual characteristics during puberty, including breast development, widening of the hips, and female fat distribution. Conversely, androgens are responsible for pubic and body hair growth, as well as acne and axillary odor.

Breast development[edit]
See also: Breast development § Biochemistry
Estrogen, in conjunction with growth hormone (GH) and its secretory product insulin-like growth factor 1 (IGF-1), is critical in mediating breast development during puberty, as well as breast maturation during pregnancy in preparation of lactation and breastfeeding.[39][40] Estrogen is primarily and directly responsible for inducing the ductal component of breast development,[41][42][43] as well as for causing fat deposition and connective tissue growth.[41][42] It is also indirectly involved in the lobuloalveolar component, by increasing progesterone receptor expression in the breasts[41][43][44] and by inducing the secretion of prolactin.[45][46] Allowed for by estrogen, progesterone and prolactin work together to complete lobuloalveolar development during pregnancy.[42][47]
Androgens such as testosterone powerfully oppose estrogen action in the breasts, such as by reducing estrogen receptor expression in them.[48][49]

Female reproductive system[edit]
Estrogens are responsible for maturation and maintenance of the vagina and uterus, and are also involved in ovarian function, such as maturation of ovarian follicles. In addition, estrogens play an important role in regulation of gonadotropin secretion. For these reasons, estrogens are required for female fertility.

Neuroprotection and DNA repair[edit]
Estrogen regulated DNA repair mechanisms in the brain have neuroprotective effects.[50]  Estrogen regulates the transcription of DNA base excision repair genes as well as the translocation of the base excision repair enzymes between different subcellular compartments.

Brain and behavior[edit]
Sex drive[edit]
See also: Sexual motivation and hormones
Estrogens are involved in libido (sex drive) in both women and men.

Cognition[edit]
Verbal memory scores are frequently used as one measure of higher level cognition. These scores vary in direct proportion to estrogen levels throughout the menstrual cycle, pregnancy, and menopause. Furthermore, estrogens when administered shortly after natural or surgical menopause prevents decreases in verbal memory. In contrast, estrogens have little effect on verbal memory if first administered years after menopause.[51] Estrogens also have positive influences on other measures of cognitive function.[52] However the effect of estrogens on cognition is not uniformly favorable and is dependent on the timing of the dose and the type of cognitive skill being measured.[53]
The protective effects of estrogens on cognition may be mediated by estrogen's anti-inflammatory effects in the brain.[54] Studies have also shown that the Met allele gene and level of estrogen mediates the efficiency of prefrontal cortex dependent working memory tasks.[55][56] Researchers have urged for further research to illuminate the role of estrogen and its potential for improvement on cognitive function.[57]

Mental health[edit]
Estrogen is considered to play a significant role in women's mental health. Sudden estrogen withdrawal, fluctuating estrogen, and periods of sustained low estrogen levels correlate with significant mood lowering. Clinical recovery from postpartum, perimenopause, and postmenopause depression has been shown to be effective after levels of estrogen were stabilized and/or restored.[58][59][60] Menstrual exacerbation (including menstrual psychosis) is typically triggered by low estrogen levels,[61] and is often mistaken for premenstrual dysphoric disorder.[62]
Compulsions in male lab mice, such as those in obsessive-compulsive disorder (OCD), may be caused by low estrogen levels. When estrogen levels were raised through the increased activity of the enzyme aromatase in male lab mice, OCD rituals were dramatically decreased. Hypothalamic protein levels in the gene COMT are enhanced by increasing estrogen levels which are believed to return mice that displayed OCD rituals to normal activity. Aromatase deficiency is ultimately suspected which is involved in the synthesis of estrogen in humans and has therapeutic implications in humans having obsessive-compulsive disorder.[63]
Local application of estrogen in the rat hippocampus has been shown to inhibit the re-uptake of serotonin. Contrarily, local application of estrogen has been shown to block the ability of fluvoxamine to slow serotonin clearance, suggesting that the same pathways which are involved in SSRI efficacy may also be affected by components of local estrogen signaling pathways.[64]

Parenthood[edit]
Studies have also found that fathers had lower levels of cortisol and testosterone but higher levels of estrogen (estradiol) than did non-fathers.[65]

Binge eating[edit]
Estrogen may play a role in suppressing binge eating. Hormone replacement therapy using estrogen may be a possible treatment for binge eating behaviors in females. Estrogen replacement has been shown to suppress binge eating behaviors in female mice.[66] The mechanism by which estrogen replacement inhibits binge-like eating involves the replacement of serotonin (5-HT) neurons. Women exhibiting binge eating behaviors are found to have increased brain uptake of neuron 5-HT, and therefore less of the neurotransmitter serotonin in the cerebrospinal fluid.[67] Estrogen works to activate 5-HT neurons, leading to suppression of binge like eating behaviors.[66]
It is also suggested that there is an interaction between hormone levels and eating at different points in the female menstrual cycle. Research has predicted increased emotional eating during hormonal flux, which is characterized by high progesterone and estradiol levels that occur during the mid-luteal phase. It is hypothesized that these changes occur due to brain changes across the menstrual cycle that are likely a genomic effect of hormones. These effects produce menstrual cycle changes, which result in hormone release leading to behavioral changes, notably binge and emotional eating. These occur especially prominently among women who are genetically vulnerable to binge eating phenotypes.[68]
Binge eating is associated with decreased estradiol and increased progesterone.[69] Klump et al.[70] Progesterone may moderate the effects of low estradiol (such as during dysregulated eating behavior), but that this may only be true in women who have had clinically diagnosed binge episodes (BEs). Dysregulated eating is more strongly associated with such ovarian hormones in women with BEs than in women without BEs.[70]
The implantation of 17β-estradiol pellets in ovariectomized mice significantly reduced binge eating behaviors and injections of GLP-1 in ovariectomized mice decreased binge-eating behaviors.[66]
The associations between binge eating, menstrual-cycle phase and ovarian hormones correlated.[69][71][72]

Masculinization in rodents[edit]
In rodents, estrogens (which are locally aromatized from androgens in the brain) play an important role in psychosexual differentiation, for example, by masculinizing territorial behavior;[73] the same is not true in humans.[74] In humans, the masculinizing effects of prenatal androgens on behavior (and other tissues, with the possible exception of effects on bone) appear to act exclusively through the androgen receptor.[75] Consequently, the utility of rodent models for studying human psychosexual differentiation has been questioned.[76]

Skeletal system[edit]
Estrogens are responsible for both the pubertal growth spurt, which causes an acceleration in linear growth, and epiphyseal closure, which limits height and limb length, in both females and males. In addition, estrogens are responsible for bone maturation and maintenance of bone mineral density throughout life. Due to hypoestrogenism, the risk of osteoporosis increases during menopause.

Cardiovascular system[edit]
Women suffer less from heart disease due to vasculo-protective action of estrogen which helps in preventing atherosclerosis.[77] It also helps in maintaining the delicate balance between fighting infections and protecting arteries from damage thus lowering the risk of cardiovascular disease.[78] During pregnancy, high levels of estrogens increase coagulation and the risk of venous thromboembolism.


vte Absolute and relative incidence of venous thromboembolism (VTE) during pregnancy and the postpartum period


Absolute incidence of first VTE per 10,000 person–years during pregnancy and the postpartum period




Swedish data A

Swedish data B

English data

Danish data


Time period

N

Rate (95% CI)

N

Rate (95% CI)

N

Rate (95% CI)

N

Rate (95% CI)


Outside pregnancy

1105

4.2 (4.0–4.4)

1015

3.8 (?)

1480

3.2 (3.0–3.3)

2895

3.6 (3.4–3.7)


Antepartum

995

20.5 (19.2–21.8)

690

14.2 (13.2–15.3)

156

9.9 (8.5–11.6)

491

10.7 (9.7–11.6)


  Trimester 1

207

13.6 (11.8–15.5)

172

11.3 (9.7–13.1)

23

4.6 (3.1–7.0)

61

4.1 (3.2–5.2)


  Trimester 2

275

17.4 (15.4–19.6)

178

11.2 (9.7–13.0)

30

5.8 (4.1–8.3)

75

5.7 (4.6–7.2)


  Trimester 3

513

29.2 (26.8–31.9)

340

19.4 (17.4–21.6)

103

18.2 (15.0–22.1)

355

19.7 (17.7–21.9)


Around delivery

115

154.6 (128.8–185.6)

79

106.1 (85.1–132.3)

34

142.8 (102.0–199.8)

–


Postpartum

649

42.3 (39.2–45.7)

509

33.1 (30.4–36.1)

135

27.4 (23.1–32.4)

218

17.5 (15.3–20.0)


  Early postpartum

584

75.4 (69.6–81.8)

460

59.3 (54.1–65.0)

177

46.8 (39.1–56.1)

199

30.4 (26.4–35.0)


  Late postpartum

65

8.5 (7.0–10.9)

49

6.4 (4.9–8.5)

18

7.3 (4.6–11.6)

319

3.2 (1.9–5.0)


Incidence rate ratios (IRRs) of first VTE during pregnancy and the postpartum period




Swedish data A

Swedish data B

English data

Danish data


Time period

IRR* (95% CI)

IRR* (95% CI)

IRR (95% CI)†

IRR (95% CI)†


Outside pregnancy

Reference (i.e., 1.00)


Antepartum

5.08 (4.66–5.54)

3.80 (3.44–4.19)

3.10 (2.63–3.66)

2.95 (2.68–3.25)


  Trimester 1

3.42 (2.95–3.98)

3.04 (2.58–3.56)

1.46 (0.96–2.20)

1.12 (0.86–1.45)


  Trimester 2

4.31 (3.78–4.93)

3.01 (2.56–3.53)

1.82 (1.27–2.62)

1.58 (1.24–1.99)


  Trimester 3

7.14 (6.43–7.94)

5.12 (4.53–5.80)

5.69 (4.66–6.95)

5.48 (4.89–6.12)


Around delivery

37.5 (30.9–44.45)

27.97 (22.24–35.17)

44.5 (31.68–62.54)

–


Postpartum

10.21 (9.27–11.25)

8.72 (7.83–9.70)

8.54 (7.16–10.19)

4.85 (4.21–5.57)


  Early postpartum

19.27 (16.53–20.21)

15.62 (14.00–17.45)

14.61 (12.10–17.67)

8.44 (7.27–9.75)


  Late postpartum

2.06 (1.60–2.64)

1.69 (1.26–2.25)

2.29 (1.44–3.65)

0.89 (0.53–1.39)


Notes: Swedish data A = Using any code for VTE regardless of confirmation. Swedish data B = Using only algorithm-confirmed VTE. Early postpartum = First 6 weeks after delivery. Late postpartum = More than 6 weeks after delivery. * = Adjusted for age and calendar year. † = Unadjusted ratio calculated based on the data provided. Source: [79]

Immune system[edit]
Estrogen has anti-inflammatory properties and helps in mobilization of polymorphonuclear white blood cells or neutrophils.[78]

Associated conditions[edit]
Researchers have implicated estrogens in various estrogen-dependent conditions, such as ER-positive breast cancer, as well as a number of genetic conditions involving estrogen signaling or metabolism, such as estrogen insensitivity syndrome, aromatase deficiency, and aromatase excess syndrome.
High estrogen can amplify stress-hormone responses in stressful situations.[80]

Biochemistry[edit]
See also: Estradiol § Biochemistry
Biosynthesis[edit]
  Steroidogenesis, showing estrogens at bottom right as in pink triangle.[81]
Estrogens, in females, are produced primarily by the ovaries, and during pregnancy, the placenta.[82] Follicle-stimulating hormone (FSH) stimulates the ovarian production of estrogens by the granulosa cells of the ovarian follicles and corpora lutea. Some estrogens are also produced in smaller amounts by other tissues such as the liver, pancreas, bone, adrenal glands, skin, brain, adipose tissue,[83] and the breasts.[84] These secondary sources of estrogens are especially important in postmenopausal women.[85]
The pathway of estrogen biosynthesis in extragonadal tissues is different. These tissues are not able to synthesize C19 steroids, and therefore depend on C19 supplies from other tissues[85] and the level of aromatase.[86]
In females, synthesis of estrogens starts in theca interna cells in the ovary, by the synthesis of androstenedione from cholesterol. Androstenedione is a substance of weak androgenic activity which serves predominantly as a precursor for more potent androgens such as testosterone as well as estrogen. This compound crosses the basal membrane into the surrounding granulosa cells, where it is converted either immediately into estrone, or into testosterone and then estradiol in an additional step. The conversion of androstenedione to testosterone is catalyzed by 17β-hydroxysteroid dehydrogenase (17β-HSD), whereas the conversion of androstenedione and testosterone into estrone and estradiol, respectively is catalyzed by aromatase, enzymes which are both expressed in granulosa cells. In contrast, granulosa cells lack 17α-hydroxylase and 17,20-lyase, whereas theca cells express these enzymes and 17β-HSD but lack aromatase. Hence, both granulosa and theca cells are essential for the production of estrogen in the ovaries.
Estrogen levels vary through the menstrual cycle, with levels highest near the end of the follicular phase just before ovulation.
Note that in males, estrogen is also produced by the Sertoli cells when FSH binds to their FSH receptors.


vte Production rates, secretion rates, clearance rates, and blood levels of major sex hormones


Sex

Sex hormone

Reproductivephase

Bloodproduction rate

Gonadalsecretion rate

Metabolicclearance rate

Reference range (serum levels)


SI units

Non-SI units


Men

Androstenedione

–

2.8 mg/day

1.6 mg/day

2200 L/day

2.8–7.3 nmol/L

80–210 ng/dL


Testosterone

–

6.5 mg/day

6.2 mg/day

950 L/day

6.9–34.7 nmol/L

200–1000 ng/dL


Estrone

–

150 μg/day

110 μg/day

2050 L/day

37–250 pmol/L

10–70 pg/mL


Estradiol

–

60 μg/day

50 μg/day

1600 L/day

<37–210 pmol/L

10–57 pg/mL


Estrone sulfate

–

80 μg/day

Insignificant

167 L/day

600–2500 pmol/L

200–900 pg/mL


Women

Androstenedione

–

3.2 mg/day

2.8 mg/day

2000 L/day

3.1–12.2 nmol/L

89–350 ng/dL


Testosterone

–

190 μg/day

60 μg/day

500 L/day

0.7–2.8 nmol/L

20–81 ng/dL


Estrone

Follicular phase

110 μg/day

80 μg/day

2200 L/day

110–400 pmol/L

30–110 pg/mL


Luteal phase

260 μg/day

150 μg/day

2200 L/day

310–660 pmol/L

80–180 pg/mL


Postmenopause

40 μg/day

Insignificant

1610 L/day

22–230 pmol/L

6–60 pg/mL


Estradiol

Follicular phase

90 μg/day

80 μg/day

1200 L/day

<37–360 pmol/L

10–98 pg/mL


Luteal phase

250 μg/day

240 μg/day

1200 L/day

699–1250 pmol/L

190–341 pg/mL


Postmenopause

6 μg/day

Insignificant

910 L/day

<37–140 pmol/L

10–38 pg/mL


Estrone sulfate

Follicular phase

100 μg/day

Insignificant

146 L/day

700–3600 pmol/L

250–1300 pg/mL


Luteal phase

180 μg/day

Insignificant

146 L/day

1100–7300 pmol/L

400–2600 pg/mL


Progesterone

Follicular phase

2 mg/day

1.7 mg/day

2100 L/day

0.3–3 nmol/L

0.1–0.9 ng/mL


Luteal phase

25 mg/day

24 mg/day

2100 L/day

19–45 nmol/L

6–14 ng/mL


Notes and sources
Notes: "The concentration of a steroid in the circulation is determined by the rate at which it is secreted from glands, the rate of metabolism of precursor or prehormones into the steroid, and the rate at which it is extracted by tissues and metabolized. The secretion rate of a steroid refers to the total secretion of the compound from a gland per unit time. Secretion rates have been assessed by sampling the venous effluent from a gland over time and subtracting out the arterial and peripheral venous hormone concentration. The metabolic clearance rate of a steroid is defined as the volume of blood that has been completely cleared of the hormone per unit time. The production rate of a steroid hormone refers to entry into the blood of the compound from all possible sources, including secretion from glands and conversion of prohormones into the steroid of interest. At steady state, the amount of hormone entering the blood from all sources will be equal to the rate at which it is being cleared (metabolic clearance rate) multiplied by blood concentration (production rate = metabolic clearance rate × concentration). If there is little contribution of prohormone metabolism to the circulating pool of steroid, then the production rate will approximate the secretion rate." Sources: See template.

Distribution[edit]
Estrogens are plasma protein bound to albumin and/or sex hormone-binding globulin in the circulation.

Metabolism[edit]
See also: Estradiol § Metabolism, and Estradiol (medication) § Metabolism
Estrogens are metabolized via hydroxylation by cytochrome P450 enzymes such as CYP1A1 and CYP3A4 and via conjugation by estrogen sulfotransferases (sulfation) and UDP-glucuronyltransferases (glucuronidation). In addition, estradiol is dehydrogenated by 17β-hydroxysteroid dehydrogenase into the much less potent estrogen estrone. These reactions occur primarily in the liver, but also in other tissues.






vte Estrogen metabolism in humans

 
 

Estradiol

Estrone sulfate

Estrone glucuronide



2-Hydroxyestrone

Estrone

4-Hydroxyestrone



2-Methoxyestrone

16α-Hydroxyestrone

4-Methoxyestrone



17-Epiestriol

Estriol

16-Epiestriol




17β-HSD
EST
STS
UGT1A3UGT1A9



CYP450
CYP450



COMT
CYP450
COMT



unidentified
17β-HSD
unidentified


Description: The metabolic pathways involved in the metabolism of estradiol and other natural estrogens (e.g., estrone, estriol) in humans. In addition to the metabolic transformations shown in the diagram, conjugation (e.g., sulfation and glucuronidation) occurs in the case of estradiol and metabolites of estradiol that have one or more available hydroxyl (–OH) groups. Sources: See template page.



Excretion[edit]
Estrogens are excreted primarily by the kidneys as conjugates via the urine.

Medical use[edit]
Main article: Estrogen (medication)
Estrogens are used as medications, mainly in hormonal contraception, hormone replacement therapy,[87] and to treat gender dysphoria in transgender women and other transfeminine individuals as part of feminizing hormone therapy.[88]

Chemistry[edit]
See also: List of estrogens
The estrogen steroid hormones are estrane steroids.

History[edit]
See also: Estradiol § History, Estrone § History, and Estrogen (medication) § History
In 1929, Adolf Butenandt and Edward Adelbert Doisy independently isolated and purified estrone, the first estrogen to be discovered.[89] Then, estriol and estradiol were discovered in 1930 and 1933, respectively. Shortly following their discovery, estrogens, both natural and synthetic, were introduced for medical use. Examples include estriol glucuronide (Emmenin, Progynon), estradiol benzoate, conjugated estrogens (Premarin), diethylstilbestrol, and ethinylestradiol.
The word estrogen derives from Ancient Greek. It is derived from "oestros"[90] (a periodic state of sexual activity in female mammals), and genos (generating).[90] It was first published in the early 1920s and referenced as "oestrin".[91] With the years, American English adapted the spelling of estrogen to fit with its phonetic pronunciation. Nevertheless, both estrogen and oestrogen are used nowadays, yet some still wish to maintain its original spelling as it reflects the origin of the word.

Society and culture[edit]
Etymology[edit]
The name estrogen is derived from the Greek οἶστρος (oistros), literally meaning "verve or inspiration" but figuratively sexual passion or desire,[92] and the suffix -gen, meaning "producer of".

Environment[edit]
A range of synthetic and natural substances that possess estrogenic activity have been identified in the environment and are referred to xenoestrogens.[93]

Synthetic substances such as bisphenol A as well as metalloestrogens (e.g., cadmium).
Plant products with estrogenic activity are called phytoestrogens (e.g., coumestrol, daidzein, genistein, miroestrol).
Those produced by fungi are known as mycoestrogens (e.g., zearalenone).
Estrogens are among the wide range of endocrine-disrupting compounds (EDCs) because they have high estrogenic potency. When an EDC makes its way into the environment, it may cause male reproductive dysfunction to wildlife.[94] The estrogen excreted from farm animals makes its way into fresh water systems.[95] During the germination period of reproduction the fish are exposed to low levels of estrogen which may cause reproductive dysfunction to male fish.[96][97]

Cosmetics[edit]
Some hair shampoos on the market include estrogens and placental extracts; others contain phytoestrogens. In 1998, there were case reports of four prepubescent African-American girls developing breasts after exposure to these shampoos.[98] In 1993, the FDA determined that not all over-the-counter topically applied hormone-containing drug products for human use are generally recognized as safe and effective and are misbranded. An accompanying proposed rule deals with cosmetics, concluding that any use of natural estrogens in a cosmetic product makes the product an unapproved new drug and that any cosmetic using the term "hormone" in the text of its labeling or in its ingredient statement makes an implied drug claim, subjecting such a product to regulatory action.[99]
In addition to being considered misbranded drugs, products claiming to contain placental extract may also be deemed to be misbranded cosmetics if the extract has been prepared from placentas from which the hormones and other biologically active substances have been removed and the extracted substance consists principally of protein. The FDA recommends that this substance be identified by a name other than "placental extract" and describing its composition more accurately because consumers associate the name "placental extract" with a therapeutic use of some biological activity.[99]

See also[edit]
List of steroid abbreviations
Breastfeeding and fertility
References[edit]
.mw-parser-output .reflist{font-size:90%;margin-bottom:0.5em;list-style-type:decimal}.mw-parser-output .reflist .references{font-size:100%;margin-bottom:0;list-style-type:inherit}.mw-parser-output .reflist-columns-2{column-width:30em}.mw-parser-output .reflist-columns-3{column-width:25em}.mw-parser-output .reflist-columns{margin-top:0.3em}.mw-parser-output .reflist-columns ol{margin-top:0}.mw-parser-output .reflist-columns li{page-break-inside:avoid;break-inside:avoid-column}.mw-parser-output .reflist-upper-alpha{list-style-type:upper-alpha}.mw-parser-output .reflist-upper-roman{list-style-type:upper-roman}.mw-parser-output .reflist-lower-alpha{list-style-type:lower-alpha}.mw-parser-output .reflist-lower-greek{list-style-type:lower-greek}.mw-parser-output .reflist-lower-roman{list-style-type:lower-roman}

^ a b c .mw-parser-output cite.citation{font-style:inherit;word-wrap:break-word}.mw-parser-output .citation q{quotes:"\"""\"""'""'"}.mw-parser-output .citation:target{background-color:rgba(0,127,255,0.133)}.mw-parser-output .id-lock-free a,.mw-parser-output .citation .cs1-lock-free a{background:linear-gradient(transparent,transparent),url("//upload.wikimedia.org/wikipedia/commons/6/65/Lock-green.svg")right 0.1em center/9px no-repeat}.mw-parser-output .id-lock-limited a,.mw-parser-output .id-lock-registration a,.mw-parser-output .citation .cs1-lock-limited a,.mw-parser-output .citation .cs1-lock-registration a{background:linear-gradient(transparent,transparent),url("//upload.wikimedia.org/wikipedia/commons/d/d6/Lock-gray-alt-2.svg")right 0.1em center/9px no-repeat}.mw-parser-output .id-lock-subscription a,.mw-parser-output .citation .cs1-lock-subscription a{background:linear-gradient(transparent,transparent),url("//upload.wikimedia.org/wikipedia/commons/a/aa/Lock-red-alt-2.svg")right 0.1em center/9px no-repeat}.mw-parser-output .cs1-ws-icon a{background:linear-gradient(transparent,transparent),url("//upload.wikimedia.org/wikipedia/commons/4/4c/Wikisource-logo.svg")right 0.1em center/12px no-repeat}.mw-parser-output .cs1-code{color:inherit;background:inherit;border:none;padding:inherit}.mw-parser-output .cs1-hidden-error{display:none;color:#d33}.mw-parser-output .cs1-visible-error{color:#d33}.mw-parser-output .cs1-maint{display:none;color:#3a3;margin-left:0.3em}.mw-parser-output .cs1-format{font-size:95%}.mw-parser-output .cs1-kern-left{padding-left:0.2em}.mw-parser-output .cs1-kern-right{padding-right:0.2em}.mw-parser-output .citation .mw-selflink{font-weight:inherit}Huether, Sue E.; McCance, Kathryn L. (2019). Understanding Pathophysiology. Elsevier Health Sciences. p. 767. ISBN 978-0-32-367281-8. Estrogen is a generic term for any of three similar hormones derived from cholesterol: estradiol, estrone, and estriol.

^ Satoskar, R. S.; Rege, Nirmala; Bhandarkar, S. D. (2017). Pharmacology and Pharmacotherapeutics. Elsevier Health Sciences. p. 943. ISBN 978-8-13-124941-3. The natural estrogens are steroids. However, typical estrogenic activity is also shown by chemicals which are not steroids. Hence, the term 'estrogen' is used as a generic term to describe all the compounds having estrogenic activity.

^ Delgado, Benjamin J.; Lopez-Ojeda, Wilfredo (20 December 2021). "Estrogen". StatPearls [Internet]. StatPearls Publishing. PMID 30855848. Estrogen is a steroid hormone associated with the female reproductive organs and is responsible for the development of female sexual characteristics. Estrogen is often referred to as estrone, estradiol, and estriol. ... Synthetic estrogen is also available for clinical use, designed to increase absorption and effectiveness by altering the estrogen chemical structure for topical or oral administration. Synthetic steroid estrogens include ethinyl estradiol, estradiol valerate, estropipate, conjugate esterified estrogen, and quinestrol.

^ Ryan KJ (August 1982). "Biochemistry of aromatase: significance to female reproductive physiology". Cancer Research. 42 (8 Suppl): 3342s–3344s. PMID 7083198.

^ Mechoulam R, Brueggemeier RW, Denlinger DL (September 2005). "Estrogens in insects". Cellular and Molecular Life Sciences. 40 (9): 942–944. doi:10.1007/BF01946450. S2CID 31950471.

^ Burger HG (April 2002). "Androgen production in women". Fertility and Sterility. 77 Suppl 4: S3-5. doi:10.1016/S0015-0282(02)02985-0. PMID 12007895.

^ Lombardi G, Zarrilli S, Colao A, Paesano L, Di Somma C, Rossi F, De Rosa M (June 2001). "Estrogens and health in males". Molecular and Cellular Endocrinology. 178 (1–2): 51–5. doi:10.1016/S0303-7207(01)00420-8. PMID 11403894. S2CID 36834775.

^ Whitehead SA, Nussey S (2001). Endocrinology: an integrated approach. Oxford: BIOS: Taylor & Francis. ISBN 978-1-85996-252-7.

^ Soltysik K, Czekaj P (April 2013). "Membrane estrogen receptors - is it an alternative way of estrogen action?". Journal of Physiology and Pharmacology. 64 (2): 129–42. PMID 23756388.

^ Micevych PE, Kelly MJ (2012). "Membrane estrogen receptor regulation of hypothalamic function". Neuroendocrinology. 96 (2): 103–10. doi:10.1159/000338400. PMC 3496782. PMID 22538318.

^ Prossnitz ER, Arterburn JB, Sklar LA (February 2007). "GPR30: A G protein-coupled receptor for estrogen". Molecular and Cellular Endocrinology. 265–266: 138–42. doi:10.1016/j.mce.2006.12.010. PMC 1847610. PMID 17222505.

^ A. Labhart (6 December 2012). Clinical Endocrinology: Theory and Practice. Springer Science & Business Media. pp. 548–. ISBN 978-3-642-96158-8.

^ Baker ME (March 2013). "What are the physiological estrogens?". Steroids. 78 (3): 337–40. doi:10.1016/j.steroids.2012.12.011. PMID 23313336. S2CID 11803629.

^ Miller KK, Al-Rayyan N, Ivanova MM, Mattingly KA, Ripp SL, Klinge CM, Prough RA (January 2013). "DHEA metabolites activate estrogen receptors alpha and beta". Steroids. 78 (1): 15–25. doi:10.1016/j.steroids.2012.10.002. PMC 3529809. PMID 23123738.

^ Bhavnani BR, Nisker JA, Martin J, Aletebi F, Watson L, Milne JK (2000). "Comparison of pharmacokinetics of a conjugated equine estrogen preparation (premarin) and a synthetic mixture of estrogens (C.E.S.) in postmenopausal women". Journal of the Society for Gynecologic Investigation. 7 (3): 175–83. doi:10.1016/s1071-5576(00)00049-6. PMID 10865186.

^ Häggström, Mikael (2014). "Reference ranges for estradiol, progesterone, luteinizing hormone and follicle-stimulating hormone during the menstrual cycle". WikiJournal of Medicine. 1 (1). doi:10.15347/wjm/2014.001. ISSN 2002-4436.

^ Lin CY, Ström A, Vega VB, Kong SL, Yeo AL, Thomsen JS,  et al. (2004). "Discovery of estrogen receptor alpha target genes and response elements in breast tumor cells". Genome Biology. 5 (9): R66. doi:10.1186/gb-2004-5-9-r66. PMC 522873. PMID 15345050.

^ Darabi M, Ani M, Panjehpour M, Rabbani M, Movahedian A, Zarean E (2011). "Effect of estrogen receptor β A1730G polymorphism on ABCA1 gene expression response to postmenopausal hormone replacement therapy". Genetic Testing and Molecular Biomarkers. 15 (1–2): 11–5. doi:10.1089/gtmb.2010.0106. PMID 21117950.

^ Raloff J (6 December 1997). "Science News Online (12/6/97): Estrogen's Emerging Manly Alter Ego". Science News. Retrieved 4 March 2008.

^ Hess RA, Bunick D, Lee KH, Bahr J, Taylor JA, Korach KS, Lubahn DB (December 1997). "A role for oestrogens in the male reproductive system". Nature. 390 (6659): 509–12. Bibcode:1997Natur.390..509H. doi:10.1038/37352. PMC 5719867. PMID 9393999.

^ "Estrogen Linked To Sperm Count, Male Fertility". Science Blog. Archived from the original on 7 May 2007. Retrieved 4 March 2008.

^ Hill RA, Pompolo S, Jones ME, Simpson ER, Boon WC (December 2004). "Estrogen deficiency leads to apoptosis in dopaminergic neurons in the medial preoptic area and arcuate nucleus of male mice". Molecular and Cellular Neurosciences. 27 (4): 466–76. doi:10.1016/j.mcn.2004.04.012. PMID 15555924. S2CID 25280077.

^ Chidi-Ogbolu N, Baar K (2018). "Effect of Estrogen on Musculoskeletal Performance and Injury Risk". Frontiers in Physiology. 9: 1834. doi:10.3389/fphys.2018.01834. PMC 6341375. PMID 30697162.

^ Lowe DA, Baltgalvis KA, Greising SM (April 2010). "Mechanisms behind estrogen's beneficial effect on muscle strength in females". Exercise and Sport Sciences Reviews. 38 (2): 61–7. doi:10.1097/JES.0b013e3181d496bc. PMC 2873087. PMID 20335737.

^ Max SR (December 1984). "Androgen-estrogen synergy in rat levator ani muscle: glucose-6-phosphate dehydrogenase". Molecular and Cellular Endocrinology. 38 (2–3): 103–7. doi:10.1016/0303-7207(84)90108-4. PMID 6510548. S2CID 24198956.

^ Koot RW, Amelink GJ, Blankenstein MA, Bär PR (1991). "Tamoxifen and oestrogen both protect the rat muscle against physiological damage". The Journal of Steroid Biochemistry and Molecular Biology. 40 (4–6): 689–95. doi:10.1016/0960-0760(91)90292-d. PMID 1958566. S2CID 44446541.

^ Frank AP, de Souza Santos R, Palmer BF, Clegg DJ (October 2019). "Determinants of body fat distribution in humans may provide insight about obesity-related health risks". Journal of Lipid Research. 60 (10): 1710–1719. doi:10.1194/jlr.R086975. PMC 6795075. PMID 30097511.

^ Brown LM, Gent L, Davis K, Clegg DJ (September 2010). "Metabolic impact of sex hormones on obesity". Brain Research. 1350: 77–85. doi:10.1016/j.brainres.2010.04.056. PMC 2924463. PMID 20441773.

^ Janssen I, Powell LH, Kazlauskaite R, Dugan SA (March 2010). "Testosterone and visceral fat in midlife women: the Study of Women's Health Across the Nation (SWAN) fat patterning study". Obesity. 18 (3): 604–10. doi:10.1038/oby.2009.251. PMC 2866448. PMID 19696765.

^ Rubinow KB (2017). "Estrogens and Body Weight Regulation in Men". Advances in Experimental Medicine and Biology. 1043: 285–313. doi:10.1007/978-3-319-70178-3_14. ISBN 978-3-319-70177-6. PMC 5835337. PMID 29224100.

^ O'Hagan FT, Sale DG, MacDougall JD, Garner SH (July 1995). "Response to resistance training in young women and men". International Journal of Sports Medicine. 16 (5): 314–21. doi:10.1055/s-2007-973012. PMID 7558529.

^ Roth SM, Ivey FM, Martel GF, Lemmer JT, Hurlbut DE, Siegel EL,  et al. (November 2001). "Muscle size responses to strength training in young and older men and women". Journal of the American Geriatrics Society. 49 (11): 1428–33. doi:10.1046/j.1532-5415.2001.4911233.x. PMID 11890579. S2CID 31872193.

^ Massaro D, Massaro GD (December 2004). "Estrogen regulates pulmonary alveolar formation, loss, and regeneration in mice" (PDF). American Journal of Physiology. Lung Cellular and Molecular Physiology. 287 (6): L1154-9. doi:10.1152/ajplung.00228.2004. PMID 15298854. S2CID 24642944. Archived from the original (PDF) on 25 February 2019.

^ Christensen, A; Bentley, GE; Cabrera, R; Ortega, HH; Perfito, N; Wu, TJ; Micevych, P (July 2012). "Hormonal Regulation of Female Reproduction". Hormone and Metabolic Research. 44 (8): 587–91. doi:10.1055/s-0032-1306301. PMC 3647363. PMID 22438212.

^ Handa RJ, Ogawa S, Wang JM, Herbison AE (January 2012). "Roles for oestrogen receptor β in adult brain function". Journal of Neuroendocrinology. 24 (1): 160–73. doi:10.1111/j.1365-2826.2011.02206.x. PMC 3348521. PMID 21851428.

^ Kow LM, Pfaff DW (May 1998). "Mapping of neural and signal transduction pathways for lordosis in the search for estrogen actions on the central nervous system". Behavioural Brain Research. 92 (2): 169–80. doi:10.1016/S0166-4328(97)00189-7. PMID 9638959. S2CID 28276218.

^ Warnock JK, Swanson SG, Borel RW, Zipfel LM, Brennan JJ (2005). "Combined esterified estrogens and methyltestosterone versus esterified estrogens alone in the treatment of loss of sexual interest in surgically menopausal women". Menopause. 12 (4): 374–84. doi:10.1097/01.GME.0000153933.50860.FD. PMID 16037752. S2CID 24557071.

^ Heiman JR, Rupp H, Janssen E, Newhouse SK, Brauer M, Laan E (May 2011). "Sexual desire, sexual arousal and hormonal differences in premenopausal US and Dutch women with and without low sexual desire". Hormones and Behavior. 59 (5): 772–9. doi:10.1016/j.yhbeh.2011.03.013. PMID 21514299. S2CID 20807391.

^ Brisken C, O'Malley B (December 2010). "Hormone action in the mammary gland". Cold Spring Harbor Perspectives in Biology. 2 (12): a003178. doi:10.1101/cshperspect.a003178. PMC 2982168. PMID 20739412.

^ Kleinberg DL (February 1998). "Role of IGF-I in normal mammary development". Breast Cancer Research and Treatment. 47 (3): 201–8. doi:10.1023/a:1005998832636. PMID 9516076. S2CID 30440069.

^ a b c Johnson LR (2003). Essential Medical Physiology. Academic Press. p. 770. ISBN 978-0-12-387584-6.

^ a b c Norman AW, Henry HL (30 July 2014). Hormones. Academic Press. p. 311. ISBN 978-0-08-091906-5.

^ a b Coad J, Dunstall M (2011). Anatomy and Physiology for Midwives, with Pageburst online access,3: Anatomy and Physiology for Midwives. Elsevier Health Sciences. p. 413. ISBN 978-0-7020-3489-3.

^ Haslam SZ, Osuch JR (1 January 2006). Hormones and Breast Cancer in Post-Menopausal Women. IOS Press. p. 69. ISBN 978-1-58603-653-9.

^ Silbernagl S, Despopoulos A (1 January 2011). Color Atlas of Physiology. Thieme. pp. 305–. ISBN 978-3-13-149521-1.

^ Fadem B (2007). High-yield Comprehensive USMLE Step 1 Review. Lippincott Williams & Wilkins. pp. 445–. ISBN 978-0-7817-7427-7.

^ Blackburn S (14 April 2014). Maternal, Fetal, & Neonatal Physiology. Elsevier Health Sciences. pp. 146–. ISBN 978-0-323-29296-2.

^ Strauss JF, Barbieri RL (13 September 2013). Yen and Jaffe's Reproductive Endocrinology. Elsevier Health Sciences. pp. 236–. ISBN 978-1-4557-2758-2.

^ Wilson CB, Nizet V, Maldonado Y, Remington JS, Klein JO (24 February 2015). Remington and Klein's Infectious Diseases of the Fetus and Newborn Infant. Elsevier Health Sciences. pp. 190–. ISBN 978-0-323-24147-2.

^ Zárate S, Stevnsner T, Gredilla R (2017). "Role of Estrogen and Other Sex Hormones in Brain Aging. Neuroprotection and DNA Repair". Frontiers in Aging Neuroscience. 9: 430. doi:10.3389/fnagi.2017.00430. PMC 5743731. PMID 29311911.

^ Sherwin BB (February 2012). "Estrogen and cognitive functioning in women: lessons we have learned". Behavioral Neuroscience. 126 (1): 123–7. doi:10.1037/a0025539. PMC 4838456. PMID 22004260.

^ Hara Y, Waters EM, McEwen BS, Morrison JH (July 2015). "Estrogen Effects on Cognitive and Synaptic Health Over the Lifecourse". Physiological Reviews. 95 (3): 785–807. doi:10.1152/physrev.00036.2014. PMC 4491541. PMID 26109339.

^ Korol DL, Pisani SL (August 2015). "Estrogens and cognition: Friends or foes?: An evaluation of the opposing effects of estrogens on learning and memory". Hormones and Behavior. 74: 105–15. doi:10.1016/j.yhbeh.2015.06.017. PMC 4573330. PMID 26149525.

^ Au A, Feher A, McPhee L, Jessa A, Oh S, Einstein G (January 2016). "Estrogens, inflammation and cognition". Frontiers in Neuroendocrinology. 40: 87–100. doi:10.1016/j.yfrne.2016.01.002. PMID 26774208.

^ Jacobs E, D'Esposito M (April 2011). "Estrogen shapes dopamine-dependent cognitive processes: implications for women's health". The Journal of Neuroscience. 31 (14): 5286–93. doi:10.1523/JNEUROSCI.6394-10.2011. PMC 3089976. PMID 21471363.

^ Colzato LS, Hommel B (1 January 2014). "Effects of estrogen on higher-order cognitive functions in unstressed human females may depend on individual variation in dopamine baseline levels". Frontiers in Neuroscience. 8: 65. doi:10.3389/fnins.2014.00065. PMC 3985021. PMID 24778605.

^ Hogervorst, E (2013). "Estrogen and the brain: does estrogen treatment improve cognitive function?". Menopause International. 19 (1): 6–19. doi:10.1177/1754045312473873. PMID 27951525. S2CID 10122688.

^ Douma SL, Husband C, O'Donnell ME, Barwin BN, Woodend AK (2005). "Estrogen-related mood disorders: reproductive life cycle factors". Advances in Nursing Science. 28 (4): 364–75. doi:10.1097/00012272-200510000-00008. PMID 16292022. S2CID 9172877.

^ Osterlund MK, Witt MR, Gustafsson JA (December 2005). "Estrogen action in mood and neurodegenerative disorders: estrogenic compounds with selective properties-the next generation of therapeutics". Endocrine. 28 (3): 235–42. doi:10.1385/ENDO:28:3:235. PMID 16388113. S2CID 8205014.

^ Lasiuk GC, Hegadoren KM (October 2007). "The effects of estradiol on central serotonergic systems and its relationship to mood in women". Biological Research for Nursing. 9 (2): 147–60. doi:10.1177/1099800407305600. PMID 17909167. S2CID 37965502.

^ Grigoriadis S, Seeman MV (June 2002). "The role of estrogen in schizophrenia: implications for schizophrenia practice guidelines for women". Canadian Journal of Psychiatry. 47 (5): 437–42. doi:10.1177/070674370204700504. PMID 12085678.

^ "PMDD/PMS". The Massachusetts General Hospital Center for Women’s Mental Health. Retrieved 12 January 2019.

^ Hill RA, McInnes KJ, Gong EC, Jones ME, Simpson ER, Boon WC (February 2007). "Estrogen deficient male mice develop compulsive behavior". Biological Psychiatry. 61 (3): 359–66. doi:10.1016/j.biopsych.2006.01.012. PMID 16566897. S2CID 22669945.

^ Benmansour S, Weaver RS, Barton AK, Adeniji OS, Frazer A (April 2012). "Comparison of the effects of estradiol and progesterone on serotonergic function". Biological Psychiatry. 71 (7): 633–41. doi:10.1016/j.biopsych.2011.11.023. PMC 3307822. PMID 22225849.

^ Berg SJ, Wynne-Edwards KE (June 2001). "Changes in testosterone, cortisol, and estradiol levels in men becoming fathers". Mayo Clinic Proceedings. 76 (6): 582–92. doi:10.4065/76.6.582. PMID 11393496.

^ a b c Cao X, Xu P, Oyola MG, Xia Y, Yan X, Saito K,  et al. (October 2014). "Estrogens stimulate serotonin neurons to inhibit binge-like eating in mice". The Journal of Clinical Investigation. 124 (10): 4351–62. doi:10.1172/JCI74726. PMC 4191033. PMID 25157819.

^ Jimerson DC, Lesem MD, Kaye WH, Hegg AP, Brewerton TD (September 1990). "Eating disorders and depression: is there a serotonin connection?". Biological Psychiatry. 28 (5): 443–54. doi:10.1016/0006-3223(90)90412-u. PMID 2207221. S2CID 31058047.

^ Klump KL, Keel PK, Racine SE, Burt SA, Burt AS, Neale M,  et al. (February 2013). "The interactive effects of estrogen and progesterone on changes in emotional eating across the menstrual cycle". Journal of Abnormal Psychology. 122 (1): 131–7. doi:10.1037/a0029524. PMC 3570621. PMID 22889242.

^ a b Edler C, Lipson SF, Keel PK (January 2007). "Ovarian hormones and binge eating in bulimia nervosa". Psychological Medicine. 37 (1): 131–41. doi:10.1017/S0033291706008956. PMID 17038206. S2CID 36609028.

^ a b Klump KL, Racine SE, Hildebrandt B, Burt SA, Neale M, Sisk CL,  et al. (September 2014). "Ovarian Hormone Influences on Dysregulated Eating: A Comparison of Associations in Women with versus without Binge Episodes". Clinical Psychological Science. 2 (4): 545–559. doi:10.1177/2167702614521794. PMC 4203460. PMID 25343062.

^ Klump KL, Keel PK, Culbert KM, Edler C (December 2008). "Ovarian hormones and binge eating: exploring associations in community samples". Psychological Medicine. 38 (12): 1749–57. doi:10.1017/S0033291708002997. PMC 2885896. PMID 18307829.

^ Lester NA, Keel PK, Lipson SF (January 2003). "Symptom fluctuation in bulimia nervosa: relation to menstrual-cycle phase and cortisol levels". Psychological Medicine. 33 (1): 51–60. doi:10.1017/s0033291702006815. PMID 12537036. S2CID 21497515.

^ Wu MV, Manoli DS, Fraser EJ, Coats JK, Tollkuhn J, Honda S,  et al. (October 2009). "Estrogen masculinizes neural pathways and sex-specific behaviors". Cell. 139 (1): 61–72. doi:10.1016/j.cell.2009.07.036. PMC 2851224. PMID 19804754.

^ Rochira V, Carani C (October 2009). "Aromatase deficiency in men: a clinical perspective". Nature Reviews. Endocrinology. 5 (10): 559–68. doi:10.1038/nrendo.2009.176. PMID 19707181. S2CID 22116130.

^ Wilson JD (September 2001). "Androgens, androgen receptors, and male gender role behavior" (PDF). Hormones and Behavior. 40 (2): 358–66. doi:10.1006/hbeh.2001.1684. PMID 11534997. S2CID 20480423. Archived from the original (PDF) on 26 February 2019.

^ Baum MJ (November 2006). "Mammalian animal models of psychosexual differentiation: when is 'translation' to the human situation possible?". Hormones and Behavior. 50 (4): 579–88. doi:10.1016/j.yhbeh.2006.06.003. PMID 16876166. S2CID 7465192.

^ Rosano GM, Panina G (1999). "Oestrogens and the heart". Therapie. 54 (3): 381–5. PMID 10500455.

^ a b Nadkarni S, Cooper D, Brancaleone V, Bena S, Perretti M (November 2011). "Activation of the annexin A1 pathway underlies the protective effects exerted by estrogen in polymorphonuclear leukocytes". Arteriosclerosis, Thrombosis, and Vascular Biology. 31 (11): 2749–59. doi:10.1161/ATVBAHA.111.235176. PMC 3357483. PMID 21836070.

^ Abdul Sultan A, West J, Stephansson O, Grainge MJ, Tata LJ, Fleming KM, Humes D, Ludvigsson JF (November 2015). "Defining venous thromboembolism and measuring its incidence using Swedish health registries: a nationwide pregnancy cohort study". BMJ Open. 5 (11): e008864. doi:10.1136/bmjopen-2015-008864. PMC 4654387. PMID 26560059.

^ 
Prior, Jerilynn C. (2018). Estrogen's Storm Season: stories of perimenopause. Vancouver, British Columbia: CeMCOR (Centre for Menstrual Cycle and Ovulation Research). ISBN 9780973827521. Retrieved 24 July 2021. [...] high estrogen amplifies your stress hormone responses to stressful things [...]

^ Häggström, Mikael; Richfield, David (2014). "Diagram of the pathways of human steroidogenesis". WikiJournal of Medicine. 1 (1). doi:10.15347/wjm/2014.005. ISSN 2002-4436.

^ Marieb E (2013). Anatomy & physiology. Benjamin-Cummings. p. 903. ISBN 978-0-321-88760-3.

^ Hemsell DL, Grodin JM, Brenner PF, Siiteri PK, MacDonald PC (March 1974). "Plasma precursors of estrogen. II. Correlation of the extent of conversion of plasma androstenedione to estrone with age". The Journal of Clinical Endocrinology and Metabolism. 38 (3): 476–9. doi:10.1210/jcem-38-3-476. PMID 4815174.

^ Barakat R, Oakley O, Kim H, Jin J, Ko CJ (September 2016). "Extra-gonadal sites of estrogen biosynthesis and function". BMB Reports. 49 (9): 488–96. doi:10.5483/BMBRep.2016.49.9.141. PMC 5227141. PMID 27530684.

^ a b Nelson LR, Bulun SE (September 2001). "Estrogen production and action". Journal of the American Academy of Dermatology. 45 (3 Suppl): S116-24. doi:10.1067/mjd.2001.117432. PMID 11511861.

^ Labrie F, Bélanger A, Luu-The V, Labrie C, Simard J, Cusan L,  et al. (1998). "DHEA and the intracrine formation of androgens and estrogens in peripheral target tissues: its role during aging". Steroids. 63 (5–6): 322–8. doi:10.1016/S0039-128X(98)00007-5. PMID 9618795. S2CID 37344052.

^ Kuhl H (August 2005). "Pharmacology of estrogens and progestogens: influence of different routes of administration". Climacteric. 8 Suppl 1: 3–63. doi:10.1080/13697130500148875. PMID 16112947. S2CID 24616324.

^ Wesp LM, Deutsch MB (March 2017). "Hormonal and Surgical Treatment Options for Transgender Women and Transfeminine Spectrum Persons". The Psychiatric Clinics of North America. 40 (1): 99–111. doi:10.1016/j.psc.2016.10.006. PMID 28159148.

^ Tata JR (June 2005). "One hundred years of hormones". EMBO Reports. 6 (6): 490–6. doi:10.1038/sj.embor.7400444. PMC 1369102. PMID 15940278.

^ a b "Origin in Biomedical Terms: oestrogen or oestrogen". Bioetymology. Retrieved 24 January 2018.

^ "Council on Pharmacy and Chemistry". Journal of the American Medical Association. 107 (15): 1221–3. 1936. doi:10.1001/jama.1936.02770410043011.

^ "Greek Word Study Tool: oistros". Perseus Digital Library. Retrieved 28 December 2011.

^ Fang H, Tong W, Shi LM, Blair R, Perkins R, Branham W,  et al. (March 2001). "Structure-activity relationships for a large diverse set of natural, synthetic, and environmental estrogens". Chemical Research in Toxicology. 14 (3): 280–94. CiteSeerX 10.1.1.460.20. doi:10.1021/tx000208y. PMID 11258977.

^ Wang S, Huang W, Fang G, Zhang Y, Qiao H (2008). "Analysis of steroidal estrogen residues in food and environmental samples". International Journal of Environmental Analytical Chemistry. 88 (1): 1–25. doi:10.1080/03067310701597293. S2CID 93975613.

^ Wise A, O'Brien K, Woodruff T (January 2011). "Are oral contraceptives a significant contributor to the estrogenicity of drinking water?". Environmental Science & Technology. 45 (1): 51–60. doi:10.1021/es1014482. PMID 20977246. Lay summary – Chemical & Engineering News. {{cite journal}}: Cite uses deprecated parameter |lay-url= (help)

^ Liney KE, Jobling S, Shears JA, Simpson P, Tyler CR (October 2005). "Assessing the sensitivity of different life stages for sexual disruption in roach (Rutilus rutilus) exposed to effluents from wastewater treatment works". Environmental Health Perspectives. 113 (10): 1299–307. doi:10.1289/ehp.7921. PMC 1281270. PMID 16203238.

^ Jobling S, Williams R, Johnson A, Taylor A, Gross-Sorokin M, Nolan M,  et al. (April 2006). "Predicted exposures to steroid estrogens in U.K. rivers correlate with widespread sexual disruption in wild fish populations". Environmental Health Perspectives. 114 Suppl 1 (Suppl 1): 32–9. doi:10.1289/ehp.8050. PMC 1874167. PMID 16818244.

^ Sanghavi DM (17 October 2006). "Preschool Puberty, and a Search for the Causes". The New York Times. Retrieved 4 June 2008.

^ a b FDA (February 1995). "Products containing estrogenic hormones, placental extract or vitamins". Guide to Inspections of Cosmetic Product Manufacturers. Archived from the original on 14 October 2007. Retrieved 24 October 2006.


External links[edit]
Nussey and Whitehead: Endocrinology, an integrated approach, Taylor and Francis 2001. Free online textbook.
.mw-parser-output .navbox{box-sizing:border-box;border:1px solid #a2a9b1;width:100%;clear:both;font-size:88%;text-align:center;padding:1px;margin:1em auto 0}.mw-parser-output .navbox .navbox{margin-top:0}.mw-parser-output .navbox+.navbox,.mw-parser-output .navbox+.navbox-styles+.navbox{margin-top:-1px}.mw-parser-output .navbox-inner,.mw-parser-output .navbox-subgroup{width:100%}.mw-parser-output .navbox-group,.mw-parser-output .navbox-title,.mw-parser-output .navbox-abovebelow{padding:0.25em 1em;line-height:1.5em;text-align:center}.mw-parser-output .navbox-group{white-space:nowrap;text-align:right}.mw-parser-output .navbox,.mw-parser-output .navbox-subgroup{background-color:#fdfdfd}.mw-parser-output .navbox-list{line-height:1.5em;border-color:#fdfdfd}.mw-parser-output .navbox-list-with-group{text-align:left;border-left-width:2px;border-left-style:solid}.mw-parser-output tr+tr>.navbox-abovebelow,.mw-parser-output tr+tr>.navbox-group,.mw-parser-output tr+tr>.navbox-image,.mw-parser-output tr+tr>.navbox-list{border-top:2px solid #fdfdfd}.mw-parser-output .navbox-title{background-color:#ccf}.mw-parser-output .navbox-abovebelow,.mw-parser-output .navbox-group,.mw-parser-output .navbox-subgroup .navbox-title{background-color:#ddf}.mw-parser-output .navbox-subgroup .navbox-group,.mw-parser-output .navbox-subgroup .navbox-abovebelow{background-color:#e6e6ff}.mw-parser-output .navbox-even{background-color:#f7f7f7}.mw-parser-output .navbox-odd{background-color:transparent}.mw-parser-output .navbox .hlist td dl,.mw-parser-output .navbox .hlist td ol,.mw-parser-output .navbox .hlist td ul,.mw-parser-output .navbox td.hlist dl,.mw-parser-output .navbox td.hlist ol,.mw-parser-output .navbox td.hlist ul{padding:0.125em 0}.mw-parser-output .navbox .navbar{display:block;font-size:100%}.mw-parser-output .navbox-title .navbar{float:left;text-align:left;margin-right:0.5em}vteEstradiolTopics
Estradiol (as a hormone)
Estradiol (as a medication)
Pharmacodynamics of estradiol
Pharmacokinetics of estradiol
Estrogen (as a hormone)
Estrogen (as a medication)
Menopausal hormone therapy
Feminizing hormone therapy
Estradiol-containing birth control pill
Combined injectable birth control
High-dose estrogen
Hydroxylation of estradiol
Esters
Estradiol acetate
Estradiol acetylsalicylate
Estradiol anthranilate
Estradiol benzoate butyrate
Estradiol benzoate cyclooctenyl ether
Estradiol benzoate
Estradiol butyrylacetate
Estradiol cyclooctyl acetate
Estradiol cypionate
Estradiol decanoate
Estradiol diacetate
Estradiol dibutyrate
Estradiol dienantate
Estradiol dipropionate
Estradiol distearate
Estradiol disulfate
Estradiol diundecylate
Estradiol diundecylenate
Estradiol enantate
Estradiol furoate
Estradiol glucuronide
Estradiol hemisuccinate
Estradiol hexahydrobenzoate
Estradiol monopropionate
Estradiol mustard
Estradiol palmitate
Estradiol phenylpropionate
Estradiol phosphate
Estradiol pivalate
Estradiol propoxyphenylpropionate
Estradiol salicylate
Estradiol stearate
Estradiol sulfamate
Estradiol sulfate
Estradiol undecylate
Estradiol undecylenate
Estradiol valerate
Estramustine phosphate (estradiol normustine phosphate)
Estrogen ester
Polyestradiol phosphate
Related
Estrone
Estriol
Estetrol
Ethinylestradiol
Conjugated estrogens
Esterified estrogens
Estrone sulfate
Estropipate (piperazine estrone sulfate)

vteHormonesEndocrineglandsHypothalamic-pituitaryHypothalamus
GnRH
TRH
Dopamine
CRH
GHRH
Somatostatin (GHIH)
MCH
Posterior pituitary
Oxytocin
Vasopressin
Anterior pituitary
FSH
LH
TSH
Prolactin
POMC
CLIP
ACTH
MSH
Endorphins
Lipotropin
GH
Adrenal axis
Adrenal cortex
Aldosterone
Cortisol
Cortisone
DHEA
DHEA-S
Androstenedione
Adrenal medulla
Adrenaline
Norepinephrine
Thyroid
Thyroid hormones
T3
T4
Calcitonin
Thyroid axis
Parathyroid
PTH
Gonadal axisTestis
Testosterone
AMH
Inhibin
Ovary
Estradiol
Progesterone
Activin
Inhibin
Relaxin
GnSAF
Placenta
hCG
HPL
Estrogen
Progesterone
Pancreas
Glucagon
Insulin
Amylin
Somatostatin
Pancreatic polypeptide
Pineal gland
Melatonin
N,N-Dimethyltryptamine
5-Methoxy-N,N-dimethyltryptamine
OtherThymus
Thymosins
Thymosin α1
Beta thymosins
Thymopoietin
Thymulin
Digestive systemStomach
Gastrin
Ghrelin
Duodenum
CCK
Incretins
GIP
GLP-1
Secretin
Motilin
VIP
Ileum
Enteroglucagon
Peptide YY
Liver/other
Insulin-like growth factor
IGF-1
IGF-2
Adipose tissue
Leptin
Adiponectin
Resistin
Skeleton
Osteocalcin
Kidney
Renin
EPO
Calcitriol
Prostaglandin
Heart
Natriuretic peptide
ANP
BNP

vteEndogenous steroidsPrecursors
Cholesterol
22R-Hydroxycholesterol
20α,22R-Dihydroxycholesterol
Pregnenolone
11β-Hydroxypregnenolone
17α-Hydroxypregnenolone
21-Hydroxypregnenolone
17α,21-Dihydroxypregnenolone
11β,17α,21-Trihydroxypregnenolone
CorticosteroidsGlucocorticoids
3α,5α-Tetrahydrocorticosterone
5α-Dihydrocorticosterone
11-Deoxycorticosterone
11-Deoxycortisol
11-Ketoprogesterone
21-Deoxycortisol
21-Deoxycortisone
Corticosterone
Cortisol
Cortisone
17α-Hydroxypregnenolone
17α-Hydroxyprogesterone
Pregnenolone
Progesterone
Metabolites: 5α-Dihydrocortisol
3α,5α-Tetrahydrocortisol
Mineralocorticoids
5α-Dihydroaldosterone
11-Dehydrocorticosterone (11-oxocorticosterone, 17-deoxycortisone)
11-Deoxycortisol
11-Deoxycorticosterone
11β-Hydroxyprogesterone (21-deoxycorticosterone)
18-Hydroxy-11-deoxycorticosterone
18-Hydroxycorticosterone
18-Hydroxyprogesterone
Aldosterone
Corticosterone
Cortisol
Sex steroidsAndrogens
11-Ketodihydrotestosterone
11-Ketotestosterone
7β-Hydroxyepiandrosterone
11β-Hydroxyandrostenedione
Adrenosterone (11-ketoandrostenedione)
Androstenediol
Androstenedione
Androsterone
Dehydroandrosterone
DHEA
DHEA sulfate
Dihydrotestosterone
Epiandrosterone
Epitestosterone
16α-Hydroxyandrostenedione
16α-Hydroxy-DHEA
16α-Hydroxy-DHEA sulfate
Testosterone
Metabolites: 3α-Androstanediol
3α-Androstanediol glucuronide
3β-Androstanediol
5β-Dihydrotestosterone
3α-Etiocholanediol
3β-Etiocholanediol
Androstanetriols
Androstenediol sulfate
Androsterone glucuronide
Androsterone sulfate
Dihydrotestosterone glucuronide
Dihydrotestosterone sulfate
Etiocholanedione
Etiocholanolone
Etiocholanolone glucuronide
Epietiocholanolone
Testosterone glucuronide
Testosterone sulfate
Estrogens
Estranes: Estetrol
Estradiol
Estrone
Estriol
17α-Estradiol
16β-Epiestriol (16β-hydroxyestradiol)
17α-Epiestriol (16α-hydroxy-17α-estradiol)
16β,17α-Epiestriol (16β-hydroxy-17α-estradiol)
2-Hydroxyestradiol
2-Hydroxyestriol
2-Hydroxyestrone
4-Hydroxyestradiol
4-Hydroxyestriol
4-Hydroxyestrone
4-Methoxyestradiol
4-Methoxyestrone
16α-Hydroxyestrone
16β-Hydroxyestrone
16-Ketoestradiol
16-Ketoestrone
Others: 27-Hydroxycholesterol
3α-Androstanediol
3β-Androstanediol
4-Androstenedione
5-Androstenediol
DHEA
DHEA sulfate
7-Keto-DHEA
7α-Hydroxy-DHEA
16α-Hydroxy-DHEA
Metabolites: 2-Methoxyestradiol
2-Methoxyestrone
2-Methoxyestriol
4-Methoxyestriol
Estradiol disulfate
Estradiol glucuronide
Estradiol 3-glucuronide
Estradiol 3-glucuronide 17β-sulfate
Estradiol sulfate
Estradiol 17β-sulfate
Estrone glucuronide
Estrone sulfate
Estriol glucuronide
Estriol sulfate
Lipoidal estradiol (e.g., estradiol stearate, estradiol palmitate)
Progestogens
Progesterone
16α-Hydroxyprogesterone
17α-Hydroxyprogesterone
20α-Dihydroprogesterone
20β-Dihydroprogesterone
5α-Dihydroprogesterone
11-Deoxycorticosterone
5α-DHDOC
Metabolites: Allopregnanediol
Pregnanediol
Pregnanediol glucuronide
Pregnanetriol
Neurosteroids
Cholestanes: 24S-Hydroxycholesterol
Cholesterol
Pregnanes: 3α-Dihydroprogesterone
3β-Dihydroprogesterone
5α-Dihydrocorticosterone
5α-Dihydroprogesterone
5β-Dihydroprogesterone
Allopregnanolone
Corticosterone
DHC
DHDOC
11-Deoxycorticosterone
Epipregnanolone
Isopregnanolone
Pregnanolone
Pregnenolone
Pregnenolone sulfate
Progesterone
THB
THDOC
Androstanes: 3α-Androstanediol
3α-Androstenol
7-Keto-DHEA
7α-Hydroxy-DHEA
7β-Hydroxy-DHEA
7α-Hydroxyepiandrosterone
7β-Hydroxyepiandrosterone
Androsterone
DHEA
DHEA sulfate
Etiocholanolone
Pheromones: 3α-Androstenol
3β-Androstenol
Androstadienol
Androstadienone
Androstenone
Androsterone
Estratetraenol
Others
Vitamin D: 7-Dehydrocholesterol
Calcidiol/Calcifediol
Calcitriol
Cholecalciferol
Others: 7α-Hydroxycholesterol
11α-Hydroxyprogesterone
11β-Hydroxyprogesterone
Cholesterol sulfate

vteEstrogens and antiestrogensEstrogensER agonists
Steroidal: Alfatradiol
Certain androgens/anabolic steroids (e.g., testosterone, testosterone esters, methyltestosterone, metandienone, nandrolone esters) (via estrogenic metabolites)
Certain progestins (e.g., norethisterone, noretynodrel, etynodiol diacetate, tibolone)
Clomestrone
Cloxestradiol acetate
Conjugated estriol
Conjugated estrogens
Epiestriol
Epimestrol
Esterified estrogens
Estetrol†
Estradiol
Estradiol esters (e.g., estradiol acetate, estradiol benzoate, estradiol cypionate, estradiol enanthate, estradiol undecylate, estradiol valerate, polyestradiol phosphate, estradiol ester mixtures (Climacteron))
Estramustine phosphate
Estriol
Estriol esters (e.g., estriol succinate, polyestriol phosphate)
Estrogenic substances
Estrone
Estrone esters
Estrone sulfate
Estropipate (piperazine estrone sulfate)
Ethinylestradiol#
Ethinylestradiol sulfonate
Hydroxyestrone diacetate
Mestranol
Methylestradiol
Moxestrol
Nilestriol
Prasterone (dehydroepiandrosterone; DHEA)
Prasterone enanthate
Prasterone sulfate
Promestriene
Quinestradol
Quinestrol
Nonsteroidal: Benzestrol
Bifluranol
Chlorotrianisene
Dienestrol
Dienestrol diacetate
Diethylstilbestrol (stilbestrol)
Diethylstilbestrol esters/ethers
Dimestrol (diethylstilbestrol dimethyl ether)
Fosfestrol (diethylstilbestrol diphosphate)
Mestilbol (diethylstilbestrol monomethyl ether)
Doisynoestrol (fenocycline)
Hexestrol
Hexestrol esters
Methallenestril
Methestrol (promethestrol)
Methestrol dipropionate (promethestrol dipropionate)
Paroxypropione
Quadrosilan
Triphenylbromoethylene
Triphenylchloroethylene
Zeranol
Progonadotropins
Antiandrogens (e.g., bicalutamide)
GnRH agonists (e.g., GnRH (gonadorelin), leuprorelin)
Gonadotropins (e.g., FSH, LH)
AntiestrogensER antagonists(incl. SERMs/SERDs)
Acolbifene†
Anordrin
Bazedoxifene
Broparestrol
Clomifene#
Cyclofenil
Enclomifene†
Epitiostanol
Lasofoxifene
Mepitiostane
Ormeloxifene
Ospemifene
Raloxifene
Tamoxifen#
Toremifene
Exclusively antagonistic: Fulvestrant
Noncompetitive inhibitors: Trilostane
Aromatase inhibitors
First-generation: Aminoglutethimide
Testolactone
Second-generation: Fadrozole
Formestane
Third-generation: Anastrozole
Exemestane
Letrozole
Antigonadotropins
Androgens/anabolic steroids (e.g., testosterone, testosterone esters, nandrolone esters, oxandrolone, fluoxymesterone)
D2 receptor antagonists (prolactin releasers) (e.g., domperidone, metoclopramide, risperidone, haloperidol, chlorpromazine, sulpiride)
GnRH agonists (e.g., leuprorelin, goserelin)
GnRH antagonists (e.g., cetrorelix, elagolix)
Progestogens (e.g., chlormadinone acetate, cyproterone acetate, gestonorone caproate, hydroxyprogesterone caproate, medroxyprogesterone acetate, megestrol acetate)
Others
Mixed mechanism of action: Danazol
Gestrinone
Androstenedione immunogens: Androvax (androstenedione albumin)
Ovandrotone albumin (Fecundin)

#WHO-EM
‡Withdrawn from market
Clinical trials:
†Phase III
§Never to phase III

See also
Estrogen receptor modulators
Androgens and antiandrogens
Progestogens and antiprogestogens
List of estrogens
vteEstrogen receptor modulatorsERAgonists
Steroidal: 2-Hydroxyestradiol
2-Hydroxyestrone
3-Methyl-19-methyleneandrosta-3,5-dien-17β-ol
3α-Androstanediol
3α,5α-Dihydrolevonorgestrel
3β,5α-Dihydrolevonorgestrel
3α-Hydroxytibolone
3β-Hydroxytibolone
3β-Androstanediol
4-Androstenediol
4-Androstenedione
4-Fluoroestradiol
4-Hydroxyestradiol
4-Hydroxyestrone
4-Methoxyestradiol
4-Methoxyestrone
5-Androstenediol
7-Oxo-DHEA
7α-Hydroxy-DHEA
7α-Methylestradiol
7β-Hydroxyepiandrosterone
8,9-Dehydroestradiol
8,9-Dehydroestrone
8β-VE2
10β,17β-Dihydroxyestra-1,4-dien-3-one (DHED)
11β-Chloromethylestradiol
11β-Methoxyestradiol
15α-Hydroxyestradiol
16-Ketoestradiol
16-Ketoestrone
16α-Fluoroestradiol
16α-Hydroxy-DHEA
16α-Hydroxyestrone
16α-Iodoestradiol
16α-LE2
16β-Hydroxyestrone
16β,17α-Epiestriol (16β-hydroxy-17α-estradiol)
17α-Estradiol (alfatradiol)
17α-Dihydroequilenin
17α-Dihydroequilin
17α-Epiestriol (16α-hydroxy-17α-estradiol)
17α-Ethynyl-3α-androstanediol
17α-Ethynyl-3β-androstanediol
17β-Dihydroequilenin
17β-Dihydroequilin
17β-Methyl-17α-dihydroequilenin
Abiraterone
Abiraterone acetate
Alestramustine
Almestrone
Anabolic steroids (e.g., testosterone and esters, methyltestosterone, metandienone (methandrostenolone), nandrolone and esters, many others; via estrogenic metabolites)
Atrimustine
Bolandiol
Bolandiol dipropionate
Butolame
Clomestrone
Cloxestradiol
Cloxestradiol acetate
Conjugated estriol
Conjugated estrogens
Cyclodiol
Cyclotriol
DHEA
DHEA-S
ent-Estradiol
Epiestriol (16β-epiestriol, 16β-hydroxy-17β-estradiol)
Epimestrol
Equilenin
Equilin
ERA-63 (ORG-37663)
Esterified estrogens
Estetrol
Estradiol
Estradiol esters
Lipoidal estradiol
Polyestradiol phosphate
Estramustine
Estramustine phosphate
Estrapronicate
Estrazinol
Estriol
Estriol esters
Polyestriol phosphate
Estrofurate
Estrogenic substances
Estromustine
Estrone
Estrone esters
Estrone methyl ether
Estropipate
Etamestrol (eptamestrol)
Ethinylandrostenediol
Ethandrostate
Ethinylestradiol
Ethinylestradiol 3-benzoate
Ethinylestradiol sulfonate
Ethinylestriol
Ethylestradiol
Etynodiol
Etynodiol diacetate
Hexolame
Hippulin
Hydroxyestrone diacetate
Lynestrenol
Lynestrenol phenylpropionate
Mestranol
Methylestradiol
Moxestrol
Mytatrienediol
Nilestriol
Norethisterone
Noretynodrel
Orestrate
Pentolame
Prodiame
Prolame
Promestriene
RU-16117
Quinestradol
Quinestrol
Tibolone
Nonsteroidal: (R,R)-THC
(S,S)-THC
2,8-DHHHC
β-LGND1
β-LGND2 (GTx-878)
AC-186
Allenestrol
Allenolic acid
Benzestrol
Bifluranol
Bisdehydrodoisynolic acid
Butestrol
Carbestrol
D-15414
DCW234
Diarylpropionitrile
Dienestrol
Dienestrol diacetate
Diethylstilbestrol
Diethylstilbestrol esters
Dimestrol (dianisylhexene)
Dimethylstilbestrol
Doisynoestrol (fenocycline)
Doisynolic acid
Efavirenz
ERB-196 (WAY-202196)
Erteberel (SERBA-1, LY-500307)
Estrobin (DBE)
Fenestrel
FERb 033
Fosfestrol (diethylstilbestrol diphosphate)
Furostilbestrol (diethylstilbestrol difuroate)
GTx-758
Hexestrol
Hexestrol esters
ICI-85966 (Stilbostat)
M2613
meso-Butestrol
meso-Hexestrol
Mestilbol
Methallenestril
Methestrol
Methestrol dipropionate
Paroxypropione
Pentafluranol
Phenestrol
Prinaberel (ERB-041, WAY-202041)
Propylpyrazoletriol
Quadrosilan
SC-3296
SC-4289
SERBA-2
SKF-82,958
Terfluranol
Triphenylbromoethylene
Triphenylchloroethylene
Triphenyliodoethylene
Triphenylmethylethylene (triphenylpropene)
WAY-166818
WAY-169916
WAY-200070
WAY-204688 (SIM-688)
WAY-214156
Unknown/unsorted: ERB-26
ERA-45
ERB-79
ZK-283197
Xenoestrogens: Anise-related (e.g., anethole, anol, dianethole, dianol, photoanethole)
Chalconoids (e.g., isoliquiritigenin, phloretin, phlorizin (phloridzin), wedelolactone)
Coumestans (e.g., coumestrol, psoralidin)
Flavonoids (incl. 7,8-DHF, 8-prenylnaringenin, apigenin, baicalein, baicalin, biochanin A, calycosin, catechin, daidzein, daidzin, ECG, EGCG, epicatechin, equol, formononetin, glabrene, glabridin, genistein, genistin, glycitein, kaempferol, liquiritigenin, mirificin, myricetin, naringenin, penduletin, pinocembrin, prunetin, puerarin, quercetin, tectoridin, tectorigenin)
Lavender oil
Lignans (e.g., enterodiol, enterolactone, nyasol (cis-hinokiresinol))
Metalloestrogens (e.g., cadmium)
Pesticides (e.g., alternariol, dieldrin, endosulfan, fenarimol, HPTE, methiocarb, methoxychlor, triclocarban, triclosan)
Phytosteroids (e.g., digitoxin (digitalis), diosgenin, guggulsterone)
Phytosterols (e.g., β-sitosterol, campesterol, stigmasterol)
Resorcylic acid lactones (e.g., zearalanone, α-zearalenol, β-zearalenol, zearalenone, zeranol (α-zearalanol), taleranol (teranol, β-zearalanol))
Steroid-like (e.g., deoxymiroestrol, miroestrol)
Stilbenoids (e.g., resveratrol, rhaponticin)
Synthetic xenoestrogens (e.g., alkylphenols, bisphenols (e.g., BPA, BPF, BPS), DDT, parabens, PBBs, PHBA, phthalates, PCBs)
Others (e.g., agnuside, rotundifuran)
Mixed(SERMs)
2-Phenylbenzofuran
2-Phenylbenzothiophene
4'-Hydroxynorendoxifen
27-Hydroxycholesterol
Acefluranol
Acolbifene
Afimoxifene
Anordiol
Anordrin
Arzoxifene
Bazedoxifene
Brilanestrant
Broparestrol
Camizestrant
Chlorotrianisene
Clomifene
Clomifenoxide
CN-55945-27
Cyclofenil
D-15413
Desmethylchlorotrianisene
Droloxifene
Elacestrant
Enclomifene
Endoxifen
Etacstil (GW-5638, DPC-974)
Ethamoxytriphetol (MER-25)
Femarelle
Fispemifene
GW-7604
ICI-55548
Idoxifene
Lasofoxifene
Levormeloxifene
LN-1643
LN-2299
LY-117018
Menerba
Miproxifene
Miproxifene phosphate
MRL-37
Nafoxidine
Nitromifene
NNC 45-0095
NNC 45-0320
NNC 45-0781
NNC 45-1506
Ormeloxifene
Ospemifene
Panomifene
Pipendoxifene
Promensil
Raloxifene
Rimostil (P-081)
Spironolactone
SS1010
Tamoxifen
TAS-108 (SR-16234)
Toremifene
Trioxifene
TZE-5323
U-11555A
U-11634
Y-134
Zindoxifene
Zuclomifene
Antagonists
(R,R)-THC
7β-Hydroxy-DHEA
Chloroindazole
Cytestrol acetate
EM-800 (SCH-57050)
Epitiostanol
ERA-90
ERB-88
Fulvestrant (ICI-182780)
Glyceollins (I, II, III, IV)
ICI-164384
MDL-101906
Mepitiostane
Methylepitiostanol
Methylpiperidinopyrazole
MIBE
Oxabicycloheptene sulfonate
Phenytoin
PHTPP
Prochloraz
RU-39411
RU-58668
SS1020
TAS-108 (SR-16234)
ZB716
ZK-164015
ZK-191703
Coregulator-binding modulators: ERX-11
Noncompetitive inhibitors: Trilostane
GPERAgonists
2-Methoxyestradiol
7β-Hydroxyepiandrosterone
Afimoxifene (4-hydroxytamoxifen)
Aldosterone
Atrazine
Bisphenol A
Daidzein
DDT (p,p'-DDT, o',p'-DDE)
Diarylpropionitrile
Equol
Estradiol
Ethinylestradiol
Fulvestrant (ICI-182780)
G-1
Genistein
GPER-L1
GPER-L2
Hydroxytyrosol
Kepone
Niacin
Niacinamide
Nonylphenol
Oleuropein
PCBs (2,2',5'-PCB-4-OH)
Propylpyrazoletriol
Quercetin
Raloxifene
Resveratrol
STX
Tamoxifen
Tectoridin
Antagonists
CCL18
Estriol
G-15
G-36
MIBE
Unknown
Diethylstilbestrol
Zearalenone

See also
Receptor/signaling modulators
Estrogens and antiestrogens
Androgen receptor modulators
Progesterone receptor modulators
List of estrogens

Authority control General
Integrated Authority File (Germany)
National libraries
France (data)
United States






